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PREFACE
The aim of this dissertation is to determine the relationship between the E3-ubiquitin ligase,
Breast Cancer Associated Gene 2 (BCA2), and Nicotinamide Mono-transferase Adenlytransferase-1 (NMNAT1) and their potential roles in the regulation of breast cancer cellular
metabolism. The inverse correlation between BCA2 and NMNAT1 was originally identified by
Dr. Jian Wang via his expert evaluation of the phospho-proteomic mass-spec-analysis performed
by Dr. Buac-Ventro in Dr. Dou’s laboratory and the proteomics core facility. The analysis
compared the mass spectroscopy (MS) phospho-proteomic profiles of MDA-MB-231 triple
negative breast cancer (TNBC) cell lines of siBCA2 relative to a siNT control utilizing siRNA
knockdown (KD) to modulate the expression of BCA2. This experiment was performed by Dr.
Buac-Ventro. The analysis was performed in triplicate, in collaboration with the Wayne State
University proteomics core facility, by Dr. Paul Stemmer. Dr. Jian Wang identified NMNAT1 as
one of the upregulated phospho-peptides, which had not been previously reported. NMNAT1 is
the master regulator of nuclear Nicotinamide Adenine Dinucleotide (NAD+) levels and in concert
with NAD-dependent deacetylase sirtuin-1 (SIRT1) has been shown to regulate the expression of
several key metabolic enzymes specific to whole cell glycolytic and Warburg metabolism
(Chiarugi, Dolle, Felici, & Ziegler, 2012).
Previous findings by Dr. Daniella Buac-Ventro identified BCA2 as a significant regulator
of adenosine monophosphate activated protein kinase (AMPK) phosphorylation/activation. Since
AMPK is the master regulator of cellular energy homeostasis, it seemed logical to investigate other
potential mechanisms wherein BCA2 might have affected cancer cell metabolism. Preliminary
research findings suggested inhibition of AMPK signaling associated with increased BCA2
vii

expression is associated with an intermediate. Hence, NMNAT1 could be a potential target of
BCA2 either directly or indirectly. Dr. Buac-Ventro’s investigation began to prove the potential
role of BCA2 in the regulation of cancer cell metabolism. Hence, prior works and analyses
conducted by Dr. Wang, Dr. Stemmer, Dr. Carruthers, Dr. Caruso, Dr. Buac-Ventro and Dr. Dou
suggested BCA2 could be a potent potential target for cancer therapeutics because cancer cell
metabolism is one of the most critical and distinct markers of all cancers, and BCA2 is primarily
overexpressed in breast cancer cells.
To generate a more stable model system for investigating the role of BCA2 in the regulation
of cancer cell metabolism, I employed a shRNA-KD model system to generate stable shRNA-KD
of BCA2 in two TNBC cell lines: MDA-MB-468, and MDA-MB-231. Dr. Buac-Ventro’s model
system provided the basis for both investigating how BCA2 might regulate the metabolic system
and the potential efficacy of targeting BCA2 for cancer cell treatment. The preliminary
experiments were intended to establish the optimum glucose concentration in the media for the
subsequent experiments.
My hope is that the discoveries made within this body of work will provide the basis for
the development of BCA2 inhibitors for the clinical treatment of TNBC. Warburg-like metabolism
is indicative of rapidly proliferating cells within the body. Cancers exhibit unique and
characteristic metabolic activity known as Warburg metabolism. Experimental evidence supports
the inhibition of Warburg metabolism as a therapeutic target in cancer treatment. NMNAT1 has
been shown to regulate cellular metabolism in association with SIRT1 (Zhang et al., 2009). These
studies support the case for further investigation into BCA2’s involvement in Warburg-like
metabolism as it relates to cancer cells.
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CHAPTER 1: INTRODUCTION
1.1

Breast cancer
According to the American Cancer Society (ACS), 13% of women in the United States

(U.S.) will be diagnosed with invasive breast cancer over the course of their lifetime (ACS, 2019).
That means one in every eight women will be diagnosed with invasive breast cancer. Further, the
ACS projects an estimated 268,600 total new cases of breast cancer annually (ACS, 2019). In
addition, the ACS predicts that another 62,930 of women will be diagnosed with a non-invasive
breast cancer (breast cancer in-situ) (ACS, 2019). Intriguingly, from 1989 to 2015 breast cancer
mortality rates significantly decreased, presumably due to early detection (mammograms),
improvements in chemotherapy and targeted treatments, as well as massive and popular campaigns
to increase breast cancer awareness and the importance of self-exams. Current statistics project
that an estimated 41,760 women will die from breast cancer this year alone (ACS, 2019).
Therefore, the frequency of breast cancer mortality is only second to lung cancer as the leading
cause of cancer deaths for women in the United States. This high incidence of mortality emphasizes
the importance of continued research into potential targets and the underlying mechanisms
responsible for the development and progression of breast cancer, and the need for novel
therapeutics for treatments to specifically target the disease.
Stage, grade, size, and phenotype are key factors that are considered when determining the
treatment and prognosis of breast cancer. Current treatment options include surgical resection,
radiation therapy, chemotherapy, endocrine (hormone) therapy, and targeted therapies (Nounou et
al., 2015), which includes the highly effective clonal antibody-based targeting technologies.
However, these antibody-based therapies are extremely expensive and specific to only a few
thoroughly delineated forms of cancer.
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Many breast cancer cases are hormone-receptor (estrogen and progesterone) or HER2 (Human
Epidermal Growth Factor Receptor 2) positive and therefore are responsive to hormone therapies
in conjunction with other chemotherapeutic treatments. A smaller subset of breast cancers is triplenegative breast cancer (TNBC), lacking estrogen, progesterone and HER2 receptors. As a result
of the lack of these targetable receptor-specific endocrine therapeutics, TNBCs are extremely
aggressive. TNBCs are associated with a poorer prognosis and are frequently found primarily in
younger patients.
The TNBC phenotype constitutes 10-20% of breast cancer cases overall (Lehmann et al.,
2011). Although the culmination of early screening, advanced diagnostics, and better/targeted
treatment options have reduced mortality rates of breast cancer patients, patients expressing the
triple negative phenotype have fewer treatment options outside of chemotherapy because they lack
“well defined molecular targets” (Lehmann et al., 2011). One such chemotherapeutic strategy that
has proven effective in multiple cancer types targets the ubiquitin proteasome system (UPS) via
inhibition of the 26S proteasome. Inhibition of the UPS has proven effective and selective in the
targeting of rapidly proliferating cancers.
1.2

The structure and function of the 26s proteasome
The 26S proteasome structure (depicted in Figure 1.1) consists of two alpha and two beta

rings. The two beta rings are found in the middle of the proteasome and form its barrel-like
structure, while the two alpha rings are found on the periphery sandwiching the beta rings together
between them (Matyskiela & Martin, 2013). The alpha rings and beta rings each contain 7- and
7- subunits. This structure makes the 20S catalytic core structure with a heptagon pore through
the center of the barrel, which is where the proteolytic activity occurs (Matyskiela & Martin, 2013).
In addition to the alpha and beta rings, the proteasome has two 19S regulatory complexes or caps
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that binds to the alpha rings. The 19S caps are the “gate keepers” to the catalytic 20S proteasome
core. The 19S caps both perform deubiquitylation and impart selectivity of targeted proteins to the
proteasome according to the specific ubiquitin (Ub)-branching patterns of the ubiquitinatedproteins (Matyskiela & Martin, 2013).
The catalytic activity of the 20S core is primarily carried out by three proteolytic sites
(Figure 1.1) (Matyskiela & Martin, 2013). The proteolytic sites include: 1.) -1 or PGPH (postglutamyl peptide hydrolase-like) or caspase-like activity; 2.) -2 (Trypsin-like); and 3.) -5
(Chymotrypsin-like (CT)) activity (Shen, Schmitt, Buac, & Dou, 2013). In the UPS, targeted
proteins are tagged with ubiquitin (Ub) moieties in variable lysine linked branching patterns
(Matyskiela & Martin, 2013). The Ub-targeted proteins are recognized by the 19S cap, which binds
the polyubiquitin chains. The rest of the protein is then linearized and guided into the proteasome
where it is degraded by 20S proteasomes into small peptides (Matyskiela & Martin, 2013). The
Ub chains are cleaved by deubiquitinating enzymes (DUBs), and the small peptide chains and the
Ub moieties are recycled (Tanaka, 2009). Recycling by DUBs allows Ub to be reused and the
small peptide sequences to be used for rapid protein synthesis (Matyskiela & Martin, 2013).
1.3

Discovery and functions of the UPS
Over the course of about 60 years, the details about the UPS were slowly discovered

through the collaboration of multiple works and researchers (De Duve, Pressman, Gianetto,
Wattiaux, & Appelmans, 1955; Etlinger & Goldberg, 1977; Hershko, Eytan, Ciechanover, & Haas,
1982; Rabinovitz & Fisher, 1964). Christian de Duve accidentally discovered lysosomes while
examining rat liver enzymes in 1955 (De Duve et al., 1955). Proteins were thought to be relatively
stable prior to this discovery. Rabinovitz and Fisher (1964) determined that another proteolytic
system must exist outside of lysosomal activity when they witnessed the rapid degradation of an
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abortive protein in rabbit reticulocytes in 1964. It was concluded that another system existed for
proteolysis since reticulocytes do not contain lysosomes (Rabinovitz & Fisher, 1964). In two
separate studies conducted in 1977 and 1978 by Etlinger, Hershko, and colleagues, it was
concluded that the proteolytic system within reticulocytes was both cell-free and energy-dependent
(Etlinger & Goldberg, 1977; Hershko et al., 1982). These findings triggered investigations into
alternative mechanisms/pathways for protein degradation.

The 26S Proteasome Structure and Functional Subunit Activities:

b-1 (Post-Glutamyl Peptide Hydrolase-like, PGPH); b-2 (Trypsin-like); and b-5 Chymotrypsin-like (CT) Activities
26S Proteasome
19S Cap

20S Core

19S Cap

Figure 1.1 26S Proteasome Structure and Functional Subunit Activities.
The 26S proteasome consists of a 20S core and one or two 19S regulatory cap or Ub binding caps.
The core consists of 2 alpha and 2 beta rings. The two beta rings are stacked together in the middle
of the core and have alpha rings on either side. Each ring consists of either 7- or 7- rings. Beta
ring enzymatic subunits consist of 3 proteolytic sites: -1 (Post-glutamyl peptide hydrolase-like,
PGPH, also known as caspase-like activity); -2 (Trypsin-like); and -5 (Chymotrypsin-like (CT)
activity).
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1.4

The discovery of the UPS and the significance in cancer and disease
Hershko and colleagues characterized the polypeptide associated with the unknown

proteolytic system from 1980-1983. The group characterized the requirement of adenosine
triphosphate (ATP) in protein breakdown. They then identified that ATP breakdown to ADP + PPi
provides the energy necessary for the activation of the proteolytic enzymes that constitute the UPS.
It was identified that ATP was essential for the tagging of proteins to be degraded, and they were
the first to demonstrate how proteins were tagged by Ubiquitin (Ub) and targeted for proteolytic
degradation.
Hershko and colleagues also identified other components of the UPS and investigated the
proteasome and the role of UPS in proteolysis. Aaron Ciechanover, Avran Hershko, and Irwin
Rose were awarded the Nobel Prize in Chemistry in 2004 as a result of their discovery and research
into the UPS and the regulatory mechanisms associated with this ATP dependent and cell free
protein degradation pathway (Ciechanover, Elias, Heller, Ferber, & Hershko, 1980; Haas, Warms,
Hershko, & Rose, 1982; Hershko, Ciechanover, Heller, Haas, & Rose, 1980; Hershko et al., 1982;
Hershko, Heller, Elias, & Ciechanover, 1983).
The discovery of the UPS established the foundation for researchers to determine the
etiology for multiple diseases from cancer to neurodegenerative diseases such as Alzheimer’s
disease. Further, the UPS has become a chemotherapeutic target in the treatment of multiple
diseases and especially liquid (blood) cancers. Proteasome inhibitors (PIs) disrupt cells’ abilities
to cycle proteins associated with cell cycle and survival pathways, thus resulting in cell death in
rapidly and actively dividing cells (Paul, 2008).
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1.4.1 The UPS pathway and ubiquitin ligases
The main function of the UPS is the catabolism of specific regulatory and deleterious
intracellular proteins (Matyskiela & Martin, 2013). The UPS is responsible for the degradation,
activation, deactivation, as well as localization of Ub-targeted proteins. As a result of the UPS’s
specific and specialized regulatory machinery, the UPS is responsible for the regulation of cell
cycle progression, deoxyribonucleic acid (DNA)-damage repair, transcriptional regulation, and
signal transduction pathways (Morreale & Walden, 2016). The UPS can control the localization
of proteins to specific cellular compartments and cytoplasmic regions within the cell (Matyskiela
& Martin, 2013). The UPS is also essential in removing deleterious and misfolded proteins from
within the cell to maintain the normal cellular activities (Morreale & Walden, 2016).
The UPS plays a critical role in the regulation of cellular functions by switching on and off
various signaling pathways within the cell. This is done through ubiquitination and subsequent
proteolytic catabolism of key regulators of those pathways (Matyskiela & Martin, 2013).
Alternatively, the UPS can regulate the activity of a targeted protein by ligating Ub moieties to
critical regions of the targeted proteins, changing the accessibility of specific binding and activity
domains, and changing the conformation of the proteins (Matyskiela & Martin, 2013). Most cancer
cells fully utilize the 26S-proteasome activities to ensure the proliferation and survival, which led
to the development and discovery of specific proteasome inhibitors (Nounou et al., 2015).
A protein must first be ubiquitinated to be targeted and degraded by the UPS (McClellan,
Laugesen, & Ellgaard, 2019). Ubiquitination is a post-translational modification process whereby
a lysine on the target protein is covalently linked to a Ub-moiety by a thioester bond. The formation
of the Ub-thioester bond is catalyzed by a series of three ubiquitinating enzymes (E1-, E2-, and
E3-ligases) (McClellan, Laugesen, & Ellgaard, 2019). The first enzyme in this series is the Ub
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activating enzyme (E1-ligase), which links lysine with the carboxyl end of Ub in an ATPdependent reaction. Secondary enzymes in the series include the Ub-conjugating enzymes (E2ligases), which receive the Ub from E1-ligases via a cytosine residue on the E2-ligase (McClellan
et al., 2019). E2-ligases possess enhanced target specificity for the third class of UPS enzymes,
the E3-ligases. E3-ligases bring specifically targeted proteins together with their corresponding
E2-ligase, conjugating the Ub transfer from the E2-ligase to a lysine residue on the targeted
protein, thus forming an iso-peptide bond (McClellan et al., 2019). E3-ligases have protein and
polypeptide motif specific targeting, allowing for targeted regulation of specific protein, thereby
determining its fate. The targeted proteins are frequently ubiquitinated several times, creating a
polyubiquitin chain with distinctive branching patterns (McClellan et al., 2019). The
polyubiquitinated proteins are then transferred to the 26S proteasome for degradation and
recycling of the Ub moieties and the cleaved peptide fragments (Figure 1.2) (McClellan et al.,
2019).
1.4.2 Classes, structure, binding-domains and activities of E3-ligases
E3-ligases are the most heterogeneous class of the three Ub-enzymes in the UPS pathway.
The different classes of E3-ligases are represented by their characteristic structural and binding
domains. The specific binding domains that characterize the different E3-ligases include N-end
Rule Ub-ligases, HECT (Homologous to the E6-AP Carboxyl Terminus), and Really Interesting
New Gene (RING) domain ligases. Their unique structural domains and binding sequences
determine their protein-target specificity (An, 2008). They have been stratified into three
classifications based on their characteristic structures: 1.) HECT; 2.) Adaptor/ (N-end rule Ub
ligases); and 3.) RING. These are further divided into monomeric and multi-subunits (An, 2008;
Burger, Amemiya, Kitching, & Seth, 2006b; Chen et al., 2006; Ohta & Fukuda, 2004).
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The Ubiquitin Proteasome System (UPS) Pathway:
E3-Ligases Determine Substrate Targeting
Modified Target
Localization and/or Activity

ATP

Repeated
Cycles and
Branching

E2

AMP
+ PPi

E3
E1

E2

E1
E1

DUB

Target
Substrate
Target
Degradation
Target
Degradation

Ubiquitin
Recycling

Figure 1.2 The UPS regulates the degradation, activation and localization of target proteins
The UPS differentially regulates the degradation, activation, localization, and complex formations
of protein structures in a dynamic and specific manner in response to differential Ub patterns. The
patterns of Ub polymerization and branching are in response to the expression profile of the E3Ligases expressed in the cells shown above. It is dynamically regulated by the differential
expression of the E3-ligases. The extensive variety (600+) of different E3s has different tissue and
cell type expression profiles. This allows for the dynamic, spatial, and selective regulation of
protein expression and activity. Therefore, E3-ligases could be potential candidates for the
development of targeted therapies that specifically inhibit key cellular pathways in cancer.

The first class of E3-ligases is the HECT domain-containing ligases. HECT domaincontaining E3-ligases consist of about 30 members, including the E6-associated protein (E6-AP),
which serves as the prototypical HECT domain ligase, as well as the prototype of the HECT
domain containing class of E3-ligases. E6-AP, together with the oncoprotein E6 promotes p53
ubiquitination and subsequent degradation (Chua, Liew, Guo, & Lane, 2015; DeHart, Perlman, &
Flint, 2015; Ooga, Suzuki, & Aoki, 2015). HECT E3-ligases consist of approximately 350 amino
acids and a C-terminal region, which are homologous to that of E6-AP (Metzger, Hristova, &
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Weissman, 2012). HECT E3-ligases also include a highly conserved active-site, as well as a
cysteine residue near the C-terminus. HECT domain E3-ligases facilitate the formation of the
thioester intermediates between the Ub moieties and their target substrates (Metzger et al., 2012).
Conversely, the N-terminal regions of HECT E3s are highly variable but may be critical to
substrate recognition and target specificity (Metzger et al., 2012).
Future development of E3-ligase targeted therapies should focus on targeting the distinct
structural domains and binding motifs that characterize the diverse classes of E3-ligases. Each of
the different E3-ligases have distinct structural domain and sequence domains that could be
targeted specifically in order to regulate a broader range of E3-ligase substrates. Because of the
high specificity of the individual E3-ligases, they are potential targets for chemotherapy if specific
inhibitors can be designed to target the E3-ligases that are upregulated in cancer (An, 2008; Ardley
& Robinson, 2005). Hence, E3-ligases represent potential candidates for the development of future
UPS-targeted therapies in cancer because many play important roles in cancer progression, and
their specificity can reduce the risk of off-target side effects (Shen, Schmitt, Buac, & Dou, 2013).
The second class comprises the adaptor or N-end rule Ub ligases. The adaptor E3-ligases
are further broken down into RING-finger, U-Box, or plant homeodomain (PHD) containing
classes (Ardley & Robinson, 2005; Dikic & Robertson, 2012; Hatakeyama & Nakayama, 2003;
Metzger, Hristova, & Weissman, 2012). Adaptor E3-ligases target protein substrates that contain
specific N-terminal residues known to destabilize protein half-lives and enhance degradation.
These residues include: Type I (Arginine (Arg), Histidine (His), and Lysine (Lys)) and Type II
(Isoleucine (Ile), Leucine (Leu), Phenylalanine (Phe), Tryptophan (Trp), and Tyrosine (Tyr))
(Trausch-Azar, Abed, Orian, & Schwartz, 2015). Originally it was unknown why proteins
containing these “destabilizing residues” in the N-terminus were more readily targeted and
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degraded by the UPS (Ardley & Robinson, 2005). However, discovery and classification of the
class of E3-ligases explained their shortened half-lives. Further research into their activity and
protein stabilities established N-end Rule E3-ligases as critical regulators of multiple short-lived
regulatory proteins. N-end rule E3-ligases include Ubiquitin Protein Ligase E3, Component NRecognin 1 (UBR1), and Ubiquitin Protein Ligase E3 Component N-Recognin 2 (UBR2) which
mediate transcriptional silencing through histone ubiquitination in a spatiotemporal specific
fashion in dividing cells, thereby regulating meiotic/mitotic spindle formation (Cole, CliftonBligh, & Marsh, 2015; Trausch-Azar et al., 2015; Turco, Gallego, Schneider, & Kohler, 2015).
The rapid degradation and fast modulation of protein degradation allows for the precise control of
cell cycle progression (Dikic & Robertson, 2012).
Finally, the RING family E3-ligases are the most well studied and classified E3-ligases in
the context of breast cancer. RING E3-ligases contain a classic C3H2C3 or C3HC4 RING finger
domain with 8 characteristic Zn2+ - coordinating residues, where X is any amino acid in the
sequence motif N-1-X(2)-2-X(9-17)-3-X(1-3)-4-X(2)-6-X (4-48)7-X(2)-8-C (Smith, Berry, &
McGlade, 2013). A RING finger domain binds to two Zn2+ atoms that serve as the platform for
binding of Ub-conjugated E2-Ligases (Jaitovich et al., 2015). The cross-link formed by the first
and third pairs of cysteine/histidine residues form the first binding site. The second and fourth
pairs of cysteine/histidine residues form the other E3-Ub-ligases, which exist and act as a single
peptide [such as murine double minute 2 (Mdm2) and X-linked IAP (XIAP)] or as multiple
component complexes [such as Skp1-Cullin-F-box protein (SCF)] (Sun, 2006). Like the other
members of the E3-ligases, RING finger E3-ligases act as a molecular scaffold bringing the E2Ub complex close to the E3-bound substrate for the direct transfer of Ub to the target protein from
the E2-ligase (Jaitovich et al., 2015).
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The RING finger E3-ubiqutin ligases constitute > 230 of the approximately 600-1000 E3ligases found in the human genome. RING-E3-ligases exhibit substrate selectivity (An, 2008;
Metzger et al., 2012). Therefore, RING finger E3-ubiqutin ligases may serve as ideal candidates
for further development of novel cancer chemotherapeutics and potential cancer biomarkers as
they display tissue, cellular-compartment, and pathway specificity (Sun, 2006).
1.4.3

Breast cancer associated gene 2 (BCA2)
Breast Cancer Associated Gene 2 (BCA2) is a RING E3-Ub ligase with promising potential

as a therapeutic target in breast cancer treatment. BCA2 protein is encoded by the human Ring
Finger Protein 115 (RNF115) gene (aka: T3A12/ZNF364/Rabring7) located on chromosome 1
(1q21.2). The BCA2 protein consists of 304 amino acids with two purported (truncated) isoforms:
RNF115-X1 (N-Terminal truncated transcript) and RNF115-X2 (C-Terminal truncated transcript)
(Burger et al., 2006b; Burger et al., 2005; Burger et al., 2010; Burger et al., 1998; Wang et al.,
2013). BCA2 contains nine exons and 1927 bases in the messenger ribonucleic acid (mRNA)
(Burger et al., 2005). Little is known about the BCA2 isoforms. However, sequence analysis and
significant data have identified the key features of the full length BCA2 protein (Burger et al.,
2006b; Burger et al., 2005; Burger et al., 2010; Burger et al., 1998; Wang et al., 2013).
BCA2 contains an N-Terminal Zinc-finger domain (amino acids 18-49), which contains
two critical mutagenic sites that are essential for BCA2 to auto-ubiquitinate (Cys-228, -231 and
Lys-26, -32), which is characteristic of many RING E3-ligases. In addition, BCA2 contains a Cterminal RING-finger domain (amino acids 227-272), from which it received its original name
RNF115 (Figure 1.3) (Wang et al., 2013). Additional features include an evolutionarily conserved
N-acetyl-alanine at residue 2 with unknown significance. However, acetylation has been shown to
affect endosomal trafficking/localization, as well as protection against degradation (Bacopulos et
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al., 2012; Buac, Kona, Seth, & Dou, 2013; Kona et al., 2012; Wang et al., 2013). The significance
of BCA2 as an oncogene has been demonstrated most clearly and comprehensively in breast
cancer. However, BCA2 may also play similar roles in other types of cancer (Gumaste et al., 2015;
Klein, 2012), as well as in viral transmission (Miyakawa et al., 2009).

Breast Cancer Associated Gene-2 (BCA2/RNF115/ZNF364): Sequence Domains
-C
NN-

Ex-1

Ex-2

Ex3

Ex-4

Ex-5

Ex-6

Ex-7

Ex-8

-C

Ex-9
-1927 BPs

Zinc Finger

AKT/ 14-3-3 Site

RING-H2 Domain

Figure 1.3 Schematic of Breast Cancer Associated gene-2 (BCA2)
The full-length Breast Cancer Associated gene-2 (BCA2) (T3A12/ZNF364/Rabring7 or RNF115)
sequence was cloned from TNBC cell line MDA-MB-468 by Dr. Angelika Burger in the lab of
Dr. Arun Seth. BCA2 is located on chromosome 1 (1q21.2) and consists of 9 exons. The mRNA
is 1927 base pairs long. BCA2 is a RING-H2-type E3 ubiquitin ligase. BCA2 contains an AKT/143-3 binding site, a zinc-finger domain near the N-terminus, and a RING-H2-finger domain near
the C-terminus. Mutation site studies revealed that lysine residues K26 and K32, located in the Nterminal Zn-finger binding domain, are responsible for its ubiquitination activity.
1.5

The role of BCA2 and AMPK in regulation of cancer cell metabolism
The AMPK energy homeostasis pathway and the Ubiquitin Proteasome System (UPS) play

critical and complementary roles in regulating whole cell homeostasis. However, both cellular
energy homeostasis (Warburg effect) and aberrant UPS activity have been observed in many
different cancers. This suggests that these two pathways may be potential therapeutic targets.
AMPK is well known as the master regulator of cellular metabolism, while the UPS is the cells’
primary regulator of protein homeostasis and turnover. Some studies have demonstrated that
AMPK activation (by using metformin) might have chemo-sensitizing or even anticancer
properties. Therefore, it is important to explore the role of the AMPK pathway in breast cancer so
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targeted therapies can be developed that specifically target the anticancer activity of AMPK
activation in novel chemotherapeutic research.
Preliminary data from the Dou Lab by Dr. Daniella Buac-Ventro demonstrated that ectopic
expression of BCA2 inhibited activation of AMPK by metformin. Furthermore, Dr. Buac-Ventro
demonstrated that AMPK activation by metformin triggered an inhibitory signaling cascade that
resulted in the transcription-independent induction of BCA2, was associated with enhanced AKT
signaling activation (Buac et al., 2013). Finally, siRNA -KD of BCA2 and pharmacological
inhibition of AKT signaling both inhibited the anticancer properties of metformin in human breast
cancer cells, suggesting that metformin in combination with an inhibitor of BCA2 could be used
for breast cancer treatment.
Interestingly, it has been shown that low concentrations of metformin (60-80μM) inhibit
glucose production and gluconeogenic gene expression in primary hepatocytes through an AMPKdependent mechanism. This suggests that AMPK may exhibit a negative feedback loop to inhibit
its own activity through AMPK’s differential role in liver tissues (increase glucose) compared to
normal cells where AMPK phosphorylation results in decreased gluconeogenesis and cell growth.
BCA2 has been shown to be highly expressed in 56% of invasive breast cancers (Brahemi
et al., 2010). In addition, BCA2 has been integrally implicated in the regulation of multiple critical
cellular metabolic processes and pathways including glucose and lipid metabolism (Arkwright et
al., 2014). Specifically, expression of BCA2 regulates the activation of adenosine mono-phosphate
activated protein kinase (AMPK) and the associated downstream pathways (Buac et al., 2013).
AMPK is a highly conserved molecule and an essential sensor of intracellular adenosine nucleotide
(ATP, ADP,AMP) levels that are activated with even a modest decrease in ATP production.
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AMPK is activated by decreases in the energy status of the cell. This promotes catabolic pathways
to generate more energy in the form of ATP.
1.6

BCA2 regulates cancer cell energy homeostasis through modulation of AMPK
AMPK is known as the master regulator of cellular homeostasis (Herzig & Shaw, 2018).

AMPK signaling is known to be dysregulated in multiple human cancers, which allows the cancer
cells to continue anabolic activities even in the absence of enough metabolites (low ATP/AMP)
for normal respiration and cellular proliferation to occur. In cancer cells, anaerobic metabolism
persists even in the presence of oxygen; this occurs by the shunting of pyruvate towards the
production of lactate and the lactic acid cycle as opposed to aerobic glycolysis that occurs in
normal cells in the presence of oxygen. AMPK activation (pAMPK) occurs by an upstream energy
sensing kinase LKB1 or the calcium influx sensing CAMKK2. LKB1 phosphorylates AMPK in
response to low cellular energy states (high AMP/ATP). However, CAMKK2 activates AMPK in
response to calcium. Activated AMPK directly phosphorylates several downstream target
substrates, which modulate cellular energy metabolism and proliferation, depending on the energy
status of the cell.
A high ratio of AMP/ATP results in the phosphorylation of AMPK (pAMPK) by allosteric
regulation of AMPK. AMP displaces ATP in the binding pocket of AMPK and thus increases
phosphorylation of AMPK by LKB1 (in response to energy status) or CAMKK2 (Arkwright et al.,
2014). The phosphorylation state of AMPK regulates a myriad of metabolic pathways leading to
the inhibition of cell growth and the enhancement of cellular respiration, as well as energy
generating processes (Koh et al., 2015). Low AMP/ATP results in dephosphorylation of AMPK,
allowing a proliferative process to progress under high energy (ATP/AMP) conditions (Arkwright
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et al., 2014). However, in cancer cells, the regulation of cellular energy and metabolic homeostasis
is dysregulated by a phenomenon known as Warburg Metabolism.
Warburg metabolism is essential to the rapid proliferation of cancer cells (Liberti &
Locasale, 2016). Warburg metabolism is characterized by a metabolic shift from aerobic to
anaerobic metabolism. By transitioning from aerobic to anaerobic metabolism, the cells can
generate energy more rapidly. In addition, anaerobic metabolism generates significantly more
biomolecules for anabolic metabolism. The combined effect of the Warburg effect is to facilitate
uncontrolled cancer cell growth even under conditions of low glucose, and low oxygen saturation.
As a result of Warburg metabolism, cancer cells can create the metabolites and energy necessary
to replicate DNA and other cellular components fast enough for rapid cellular proliferation (Liberti
& Locasale, 2016). In addition, solid tumors are generally associated with dynamic
microenvironments that result in pockets of low oxygen and increased acidity (Estrella et al.,
2013). Oxygen is an essential component of aerobic oxidative phosphorylation (Epstein, Xu,
Gillies, & Gatenby, 2014). Under normal cellular conditions, low energy status is determined by
the increased ratio of AMP relative to ATP (AMP/ATP). Hence, Warburg metabolism drives the
cell towards rapid cellular proliferation by directing the cell to increase glucose consumption,
while reducing its oxygen dependency and rate of anaerobic metabolism, thereby increasing the
accumulation of metabolic intermediates for rapid growth (Liberti & Locasale, 2016).
Regulation of AMPK activation by BCA2 suggests that BCA2 plays a key role in the
regulation of cellular metabolism (Arkwright et al., 2014). Endogenous and exogenous BCA2
expression has been shown to play a critical and energy independent role in the activation of
AMPK (pAMPK). As a result of the activation of AMPK by phosphorylation, mTOR activation
is inhibited, which drives cellular proliferation (Memmott & Dennis, 2009). In addition, AMPK
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activation, either via direct AMPK activators like 5-Aminoimidazole-4-carboxamide
ribonucleotide (AICAR) or the indirect AMPK activators like metformin, has been shown to
induce expression of BCA2. This suggests a potential feedback mechanism that could be AKTdependent (Arkwright et al., 2014; Buac et al., 2013). BCA2 contains a purported AKT binding
site, and AKT is known to play a critical role in the maintenance of cellular energy metabolism
(Arkwright et al., 2014; Memmott & Dennis, 2009). Further, inhibition of AKT activation in the
presence of AMPK activators has been shown to inhibit increases in BCA2 expression associated
with AMPK activation (Arkwright et al., 2014). However, direct interaction between BCA2 and
AKT or AMPK has yet to be elucidated (Bacopulos et al., 2012; Buac et al., 2013; Kona et al.,
2012) and the exact mechanism by which enhanced BCA2 expression diminishes AMPK
activation is unclear.
Experimental evidence also strongly suggests that inhibition of BCA2 by siRNA results in
increased AMPK activation, decreased cellular proliferation, and decreased colony forming ability
(Arkwright et al., 2014). In addition, cells with diminished BCA2 expression have been shown to
exhibit increased sensitivity to the anti-proliferative and anti-cancer effects of metformin (Buac et
al., 2013). Therefore, BCA2 may be an ideal candidate for further development of UPS targeted
therapies, alone or in combination with other types of chemotherapeutics. Further, BCA2 exhibits
a unique and specific expression profile with enhanced expression in metastatic breast cancer cells
and low expression in normal tissues. There is evidence that BCA2 also plays a critical role in
aberrant cellular metabolism in cancer progression (Warburg effect) and cancer metastasis (Koh
et al., 2015).
Experimental evidence suggests that BCA2 can modulate key variables in energy
homeostasis, thereby ensuring cancer proliferation and survival even in harsh microenvironments
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(Buac et al., 2013; Burger et al., 2005). Based on these findings, the relationship of BCA2 with
other catalytic proteins was assessed to determine potential target proteins by phospho-proteomic
mass spectrum (MS) analysis (Buac et al., 2013). Dr. Buac-Ventro first conducted the transfection
of siBCA2 knockdown (KD) and siNon-targeting (NT) controls in the TNBC cell line MDA-MB231 and subsequently evaluated the KD of BCA2 protein expression by western blot analysis.
Samples were then provided to Dr. Paul Stemmer who conducted the MS technical analysis at the
Wayne State University Proteomics core facility. Phosphoproteins were enriched from both
conditions in triplicate using titanium dioxide (TiO2), then the expression profiles of both
conditions were analyzed to determine phosphoproteins regulated by BCA2 expression. It was
expected that the changes in cellular energy metabolism associated with BCA2 expression was the
result of phosphorylation of AMPK via some intermediary between BCA2 and AMPK, possibly
targeted for degradation by the proteasome after Ub-targeting by BCA2. Alternatively, AMPK
may have been phosphorylating a specific messenger protein downstream of AMPK that was
affecting the cells’ metabolism (Buac et al., 2013).
The data generated in the MDA-MB-231-siBCA2 model system revealed 36 phosphoproteins of interest (Figure 1.4) specifically upregulated in the siBCA2-KD condition (Buac et al.,
2013). Nicotinamide Mononucleotide Adenylyl-Transferase-1 (NMNAT1) was one of those 36
proteins found to be correlated with BCA2-KD. NMNATs are the key enzyme in Nicotinamide
Adenine Dinucleotide (NAD) synthesis, and there are three known isoforms (NMNAT1-3), which
are localized in different cellular compartments, suggesting differential roles in regulation of NAD
metabolism. NMNAT1 localizes to the nucleus (Zhang et al., 2009) and is suggested to suppress
tumors and is associated with better patient outcomes (Greenwald et al., 2016; Sultani et al., 2018).
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Preliminary research findings warranted further investigation into the association between
BCA2 and NMNAT1. BCA2 is suggested to play a role in the inhibition of AMPK activation and
downstream pathways (Burger et al., 2010). Prior research findings suggest that BCA2 can inhibit
the activation of AMPK in the presence of the AMPK activators, such as Metformin (Buac, Kona,
Seth, & Dou, 2013). Metformin is suggested to play a role in the activation of cellular energy
homeostasis and the utilization of glucose levels in the cell. Glucose concentration plays a critical
role in the regulation of AMPK activation and cancer cell aggressiveness (increased proliferation)
even in a cellular state of low energy as determined by the ratio of AMP/ATP (Buac et al., 2013;
Ohta & Fukuda, 2004; Shen et al., 2013). A high AMP/ATP ratio suggests that a cell is in a nutrient
deprived state, which generally activates AMPK (phosphorylated AMPK: pAMPK). It was also
determined previously by Dr. Daniella Buac-Ventro in Dr. Q. Ping Dou’s lab that there was no
direct interaction between BCA2 and AMPK phosphorylation (Buac et al., 2013). Therefore, the
inhibition of AMPK signaling associated with increased BCA2 expression suggests an association
with some intermediate. BCA2 in breast cancer is known to be upregulated in metastatic TNBCs.
NMNAT1 is known to play a critical role in the regulation of nuclear NAD+ levels in the nucleus,
which plays a key role in transcription regulation of multiple genes associated with cellular energy
homeostasis. As a result of NMANT1s known role in sensing cell energy status in complex with
the sirtuins (e.g., SIRT1), it was suspected that NMNAT1 may play a role in the regulation of
cellular energy homeostasis in TNBCs. Based on the phospho-proteomic data, the following
experiments were performed under the assumption that the amount of phosphorylated NMNAT1
(pNMNAT) would correlate with the total NMNAT1 protein expression, and that BCA2 may
regulate cellular energy metabolism through control of NMNAT1 activity. The investigation began
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by verifying the relationship between BCA2 and NMNAT1 expression in response to stable
shBCA2-KD.
A. Phospho-Peptide Enrichment (MS)
Contro

60
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96
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Figure 1.4 Venn Diagram of Phospho-proteomic Analysis of siBCA2-KD Identified
pNMAT1 as Inversely Correlated with BCA2 Protein Expression.
Following siBCA2-KD, a phospho-peptide enrichment by TiO2 pull down of the phosphorylated
proteins was performed and an MS analysis of the proteins in the MDA-MB-231-siBCA2 cells
was performed by Dr. Buac-Ventro. Analysis of the siBCA2 populations of proteins relative to the
siNT control population was performed. The Venn diagram identified 36 proteins which were
significantly changed under the siBCA2-KD conditions. B.) Further investigation of the siBCA2KD population by Dr. Jian Wang identified NMNAT1 as a potential target protein of BCA2.

1.7

Nicotinamide mono-nucleotide adenylyl-transferase (NMNAT1)
NAD+ is a coenzyme that plays a critical role in cellular energy metabolism, including

glycolysis, in which it is used to convert glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate
via glyceraldehyde-3-phophate dehydrogenase, forming reduced nicotinamide adenine
dinucleotide (NADH) (Chiarugi et al., 2012). NADH can then be used to convert pyruvate to
lactate via lactate dehydrogenase isoform A (LDHA), which forms an abundance of NAD+ in the
cytoplasm. NAD+ also plays a role in signal transduction. In the nucleus, NAD+ helps activate
enzymes that regulate and protect DNA, as well as transcription factor binding and transcriptional
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activity (Brooks, 2010; Chiarugi et al., 2012; Jayaram, Kusumanchi, & Yalowitz, 2011). In a
healthy cell, there is a higher ratio of NAD+ to NADH than in a cancerous cell (Moreira et al.,
2016).
NMNAT (Nicotinamide Mononucleotide Adenylyl-Transferase) is the rate limiting
enzyme responsible for the biosynthesis of NAD+ from NMN (Nicotinamide Mononucleotide) and
ATP (Chiarugi et al., 2012; Jayaram et al., 2011). Three different isoforms of NMNAT have been
identified and found to localize to different compartments of the cell. NMNAT3 is found in the
mitochondria and is a homo-tetramer, NMNAT2 is found in the cytoplasm (chromosome 1q25)
and is a homodimer, and NMNAT1 is found in the nucleus (chromosome 1 p32-35) and is a homohexamer with four exons and 290 base pairs (Jayaram et al., 2011). The NMNAT1 monomeric
structure consists of a central six-stranded parallel β-sheet surrounded by several helices and a
pyridine-binding site, which might play a role in the substrate recognition.
NMNAT1 appears to play a key role in regulating transcription, as NAD is critical to
transcriptional activity (NCBI, 2019; Werner et al., 2002). The biosynthetic action of NMNAT1
increases signaling of the PARP1 [Poly (ADP Ribose) Polymerase] enzyme within the nucleus.
This enzyme is thought to account for the bulk of NAD+ degradation. Therefore, it is plausible that
an increase in NMNAT1 could result in a greater reduction of NAD+ via PARP1. PARP1 and
SIRT1 (NAD-dependent deacetylase sirtuin-1) activation slow the rate of glycolysis and reduce
the amount of NADH produced. In addition to NMNAT1’s biosynthetic and regulatory actions on
NAD+, it also plays a crucial role in DNA-damage repair. NMNAT1 coupled with poly ADPRibose and SIRT1 results in the relaxation of chromatin, allowing for enhanced interactions
between chromatin regulatory elements and transcriptional factors (Schreiber, Dantzer, Ame, &
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de Murcia, 2006). Enhanced NMNAT1 activity may play a role in the regulation of the
transcription of glucose metabolic enzymes, overall cellular metabolism, and proliferation.
1.8

The Warburg effect
In the early 20th century, a German physiologist by the name of Otto Heinrich Warburg

determined that cancer cells exhibit increased rates of glycolysis even in the presence of normal
oxygen (Warburg, Wind, & Negelein, 1927). This phenomenon was termed the Warburg effect
and closely resembles aerobic glycolysis (Figure 1.5). It is well known today that the Warburg
effect is a hallmark characteristic of cancer cells (Arora et al., 2015; Liberti & Locasale, 2016;
San-Millan & Brooks, 2017). It consists of a major metabolic shift where cellular energy
metabolism is reprogrammed to primarily anaerobic metabolism. Regulation of cellular energy
metabolism is a critical aspect of cancer metabolism in order to produce the metabolites necessary
for rapid proliferation, as well as the excess energy needed to duplicate the DNA and other cellular
components (Burns & Manda, 2017; Liberti & Locasale, 2016).
The Warburg effect is a well-known phenomenon by which cancer cells revert toward the
less efficient yet rapid anaerobic glycolytic glucose metabolism in lieu of oxidative
phosphorylation, even in the presence of oxygen (Liberti & Locasale, 2016). The Warburg-like
effect is characterized by an increase in glucose consumption, decreased oxygen consumption, and
increased lactate production through the enhanced activity of lactate dehydrogenase (LDH). LDH
consists of a high activity state (LDHA) and a lower activity state (LDHB). When LDHA
predominates, the cells trend towards the production of lactate and anaerobic metabolism, while
LDHB trends towards oxidative phosphorylation and the TCA Cycle (Burns & Manda, 2017). The
result of this shift in energy metabolism thereby results in increased lactate production, and an
increase in glycolytic intermediates, providing the energy and necessary metabolites for rapid
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cancer-cell proliferation (San-Millan & Brooks, 2017). Aerobic glycolysis is also characterized by
increased acidity in the surrounding tissues or media, which is primarily caused by the increase in
lactate production. Thus, the primary characteristics of the Warburg effect are increased glucose
uptake, decreased oxygen consumption, increases in the ratio of LDHA/LDHB, increased lactate
production, and decreased pH of the media or cellular microenvironment (Burns & Manda, 2017).

Figure 1.5: Transition from Aerobic Cellular Metabolism to Anaerobic (Warburg) Metabolism
A fundamental change that occurs in metastatic transformation is the transition from normal
(aerobic) oxidative phosphorylation (normal glucose metabolism) to anaerobic metabolism
(lactate pathway). This transition is known as the Warburg effect. The Warburg effect is
characterized by significant increases in glucose consumption, decreased utilization of oxygen,
and increased production of lactate and increased accumulation of metabolic intermediates for
enhanced cancer cell proliferation and tumor growth. Under normal conditions, cells preferentially
utilize aerobic oxidative phosphorylation, which processes glucose into pyruvate, which then
enters the mitochondria and the TCA-Cycle to produce ATP. However, cancer cells preferentially
undergo anaerobic metabolism even in the presence of oxygen. Anaerobic metabolism is
characterized by the rapid consumption of glucose and the processing of glucose by LDHA into
lactate. This process provides both the energy and metabolic intermediates necessary for rapid
cellular proliferation of cancer cells. Lactate metabolism (anaerobic) is far less efficient at
converting glucose into energy (ATP), so the cells consume significantly more glucose. The
increased lactate production also increases the acidity of the surrounding microenvironment,
further changing the behavior of the tumor cells, thereby facilitating invasion and metastasis.
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In normal cells, energy is primarily derived from within the mitochondria by oxidative
phosphorylation via the TCA cycle that generates 36 mols of ATP per mol of glucose. The oxygendependent process of oxidative phosphorylation is more efficient in producing energy in the form
of ATP from glucose. However, cancer cells “modify” their metabolism to use the less efficient
but more rapid energy-producing pathway (anaerobic glycolysis), which rapidly processes glucose
and results in the formation of critical metabolites for cellular proliferation. Cancer cells upregulate
their intake of glucose in order to accommodate enough cellular metabolism to produce the energy
and glycolytic metabolites for rapid anabolic growth. In a normal cell, glucose enters the cell and
is converted primarily into pyruvate and a small fraction into lactate. In the presence of oxygen,
pyruvate enters the mitochondria for oxidative phosphorylation. In the absence of oxygen,
pyruvate is converted to lactate, which produces an excess of primary metabolites, which results
in a quicker production of energy to be stored in reservoirs of the cell (Burns & Manda, 2017).
In cancer cells, even when oxygen is prevalent, 85% of pyruvate is converted to lactate,
and only 5% undergo oxidative phosphorylation (Vander Heiden, Cantley, & Thompson, 2009).
The glycolytic pathway is further supported by the production of NAD+ as a result of pyruvate
being converted to lactate. Aerobic glycolysis is also found in normal rapidly proliferating cell
types in addition to cancer cells and under conditions of low oxygen, such as exercise. However,
normal cells that exhibit aerobic glycolysis only use this type of metabolism for a definitive amount
of time, and the mitochondria are not damaged (Burns & Manda, 2017). As in embryonic cells,
once the cell has completed rapid growth, it converts to oxidative phosphorylation. Hence, aerobic
glycolysis is a property of rapidly proliferating cells, not just cancer cells (Krisher & Prather,
2012). It is theorized that cancer cells use anaerobic metabolism over oxidative phosphorylation
because it is faster at the production of ATP in order to meet the energy needs of the cell (Burns
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& Manda, 2017; Zdralevic et al., 2018). In addition, anaerobic metabolism produces more
biosynthetic metabolites for the prolific needs of the cells (Burns & Manda, 2017).
Specifically, rapidly proliferating cells require a build-up of both glycolytic intermediates
and metabolites for the creation of new cells [For example, lipids, fatty acids, proteins, DNA, and
R5P (ribose-5-phosphate)) are required (Krisher & Prather, 2012)]. A probable explanation of how
aerobic glycolysis is activated is via overexpression of HIF1 (Hypoxia Inducible Factor 1). HIF1
is a master transcriptional regulator (transcription factor) of cellular and developmental responses
to hypoxia (Koh et al., 2015). In cancer cells, there is an overexpression of HIF, which increases
the transcription of multiple genes that encode for proteins that favor cancer proliferation. Cancer
favoring proteins will increase glucose consumption and angiogenesis and facilitate apoptosis
resistance (Koh et al., 2015; San-Millan & Brooks, 2017).
In 1966, Otto Warburg stated that “cancer, above all other diseases, has countless
secondary causes. But, even for cancer, there is only one prime cause. Summarized in a few words,
the primary cause of cancer is the replacement of the respiration of oxygen in normal body cells
by a “fermentation of sugar” (Brand, 2010, p. 2). Hence, the consumption of glucose is an essential
step in cancer cell proliferation. It is only through the increase in glucose consumption that cancer
cells can meet the biosynthetic needs for rapid cell proliferation (Burns & Manda, 2017).
HIF1 increases glucose consumption by upregulating glucose transporter 1 (GLUT1) on
the surface of the cell, allowing more glucose to enter the cell more rapidly (Baumann, Zamudio,
& Illsley, 2007; Koh et al., 2015). In addition, this upregulation of GLUT1 increases the
consumption of glucose. HIF1 also increases glucose phosphorylation through the induction of the
glycolytic enzyme hexokinase (HK), thereby converting glucose to glucose-6-phosphate. An
increase in HIF1 modulates an increase in glycolytic flux, causes a reduction in ATP production
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via oxidative phosphorylation, and decreases oxidation of pyruvate by inducing pyruvate
dehydrogenase kinase. All of this induces aerobic glycolysis (Baumann et al., 2007). Although the
glycolytic pathway is not as efficient in producing ATP as oxidative phosphorylation, if the amount
of glucose is high within the cell, the ATP production rate is sufficient for rapid cell proliferation
(Burns & Manda, 2017).
The importance of lactate is more than just a byproduct of anaerobic metabolism and an
increased energy source in cancer cells. Lactate has a significant role in normal physiology, as well
as in the treatment of injuries and illnesses (Burns & Manda, 2017). The importance of lactate and
anaerobic metabolism as an energy source for cancer cells has been extensively studied in recent
years (Burns & Manda, 2017; Liberti & Locasale, 2016; Moreira et al., 2016; San-Millan &
Brooks, 2017; Vander Heiden et al., 2009; Zdralevic et al., 2018). It also plays a key role in aerobic
glycolysis in healthy skeletal muscle, and ultimately influences changes in metabolic gene
expression (Bourdeau Julien, Sephton, & Dutchak, 2018; Burns & Manda, 2017).
In cancer cells, lactate promotes carcinogenesis and cancer cell proliferation
(tumorigenesis) under nutrient “stressed” conditions due to its acidifying effects. Unfortunately,
cancer cells exhibiting an abundance of lactate are associated with increased resistance to both
chemotherapy and radiotherapy, increased angiogenesis, increased frequency of metastasis, and
immune system evasion (Molina, Morlacchi, Silva, Dennison, & Mills, 2014). Research has
concluded that lactate production promotes cancer cell survival rates by facilitating the production
of energy in the form of ATP, increasing reduced nicotinamide adenine dinucleotide phosphate
(NADPH), glutathione, and the production of an excess of non-essential amino acids required for
rapid cellular proliferation. This information suggests that lactate metabolism in cancer cell
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biology is a potential target for the development of novel chemotherapeutic compounds (Molina
et al., 2014).
1.8.1 Lactate dehydrogenase A/B (LDHA/B)
LDH is the rate limiting enzyme in the conversion of pyruvate to lactate (Jafary,
Ganjalikhany, Moradi, Hemati, & Jafari, 2019; Lu, Zhang, Yee, Go, & Lee, 2015; Rani & Kumar,
2019). LDH has two isoforms that regulate the conversion from pyruvate to lactate, utilizing the
reducing potential of NADH, which is produced by NMNAT1, the key enzyme in NAD+
production in the nucleus (Lu et al., 2015). The high activity isoform of the LDH enzyme is LDHA.
Therefore, LDHA converts pyruvate to lactate very quickly, thereby depleting the amount of
pyruvate that can enter the mitochondria and enter the TCA cycle. It has been demonstrated
experimentally that oxamate inhibits the activity and expression of LDHA, resulting in a decrease
in glucose consumption and lactate production (Lu et al., 2015). In addition, the same paper
showed that the main pharmacologically active compound in green tea, epigallocatechin gallate
(EGCG), also decreased the expression of LDHA, increased aerobic oxidative-phosphorylation,
and decreased anaerobic lactate metabolism and production. Thus, the inhibition of LDHA results
in a dramatic impact on multiple metabolic pathways (Jafary et al., 2019; Lu et al., 2015).
LDHB is another isoform of LDH, which is the less active form of the tetra-hetero-enzyme.
LDHB converts pyruvate more slowly, allowing more pyruvate to enter the mitochondria and
oxidative phosphorylation via the TCA cycle (Rani & Kumar, 2019). In cancer cells, LDHA is the
predominantly expressed isoform in normal tissues. Hence, an increase in LDHA results in
increased lactate, which is then shuttled outside of the cell, where it lowers the pH of the
microenvironment (Zdralevic et al., 2018). In addition, increased production of lactate also
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provides the cancer cell with enough metabolic intermediates and energy for the rapid proliferation
and increased tumor growth (Rani & Kumar, 2019).
1.9

Motivation and approach
Exploiting cancer cell metabolism as an anticancer therapeutic strategy has garnered much

attention in recent years (Martinez-Outschoorn, Peiris-Pagés, Pestell, Sotgia, & Lisanti, 2016;
Weinberg & Chandel, 2014; Zdralevic et al., 2018). As previously discussed, the German scientist
Otto Heinrich Warburg observed that cancer cells consistently display an increased rate of glucose
consumption, as well as high rates of aerobic glycolysis (Brand, 2010; Warburg et al., 1927) which
results in increased lactate production.
The transition from the oxidative phosphorylation (aerobic metabolism) to the anaerobic
(lactate) metabolism is known as the Warburg effect (Burns & Manda, 2017; Warburg et al., 1927).
This shift in cellular energy metabolism is a fundamental and essential characteristic of metastatic
transformation. The composition of the cancer cells biosynthetic (anabolic) metabolic enzymes
also change in response to the shifts in the cells catabolic enzyme profile observed during
metastatic transformation. The balance of these catabolic and anabolic enzymes is dynamically
and tightly regulated in order to continually balance the energy needs of cells catabolic activity of
the cancer cells (Burns & Manda, 2017). The complexity of the metabolic pathways makes
identifying key regulators or therapeutic targets in cancer a difficult task. However, today, our
current understanding of the Warburg effect is that it is mediated by several factors, including
overexpression of the insulin-independent glucose transporter GLUT1 and various glycolytic
enzymes, including LDHA (Lu et al., 2015; Molina et al., 2014; Rani & Kumar, 2019).
LDHA is the enzyme that catalyzes the reversible conversion of pyruvate and lactate (Rani
& Kumar, 2019). During the conversion of pyruvate to lactate, the energy released facilitates the
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oxidization of NADH to NAD+ (Chiarugi et al., 2012). The lactate produced in this reaction is
largely excreted into the tumor’s microenvironment, where it acidifies surrounding tissues and
helps the tumor evade destruction by immune cells (Estrella et al., 2013). The oxidation of NADH
to NAD+ allows for continued ATP production through glycolysis (Brooks, 2010; Epstein et al.,
2014). Cell culture and in-vivo studies targeting LDHA utilizing RNA interference demonstrated
a substantial decrease in cell and tumor cell growth and proliferation. These findings support the
hypothesis that LDHA could be a viable anticancer target (Feng et al., 2018; Lu et al., 2015; Rani
& Kumar, 2019).
BCA2 is a Zn-H2-RING-Finger E3 ubiquitin ligase (Burger, Amemiya, Kitching, & Seth,
2006a). Previous studies have shown that there is an inverse correlation between BCA2 protein
expression and the activation of AMPK (Arkwright et al., 2014; Buac et al., 2013). BCA2 was
shown to inhibit the activation of AMPK (phosphorylation), which activates catabolic metabolism
in order to generate more energy under low energy states. Activation of AMPK occurs in response
to low levels of ATP and high levels of AMP (Low ATP/AMP Ratio) (Arkwright et al., 2014;
Mihaylova & Shaw, 2011). Dr. Buac-Ventro demonstrated that enhanced expression of BCA2
protein inhibited AMPK activation. In order to better understand the relationship between BCA2
and AMPK activation, siRNA targeting BCA2 was used to inhibit BCA2 protein expression in
MDA-MB-231 cells, and a phospho-peptide mass spectral analysis was performed to identify
proteins with enriched phosphorylation. This study revealed an inverse correlation between BCA2
and pNMNAT1 in response to siBCA2-KD and suggests that BCA2 may play a role in the
regulation of other metabolic processes (Buac et al., 2013).
The motivation for the current investigation was based on the identification of the inverse
correlation between BCA2 and NMNAT1 by Dr. Daniela Buac-Ventro (Buac et al., 2013). Dr.
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Buac-Ventro’s performed the siRNA-KD of BCA2 and the mass spectra analysis, and Dr. Dou
and Dr. Jian Wang identified the inverse correlation between BCA2 and NMNAT1.
After establishing that BCA2 and NMNAT1 were inversely correlated in the pilot studies
(mass-spec and in-silico analysis of transcript expression), the study began to define the
experimental parameters of the future studies. AMPK activation is known to be regulated by
glucose concentration (Salt et al., 1998). The preliminary experiments were designed to establish
the ideal glucose concentration for the remaining of the study. In order to study the effects of
glucose on the model system, increasing concentrations of glucose were applied to MDA-MB-468
and MDA-MB-231 TNBCCs. The study revealed that BCA2 protein expression was induced by
increasing glucose concentration, and BCA2 expression decreased in response to glucose
deprivation. These findings revealed an inverse correlation between BCA2 and glucose
concentration, which was associated with a concurrent change in NMNAT1 protein expression
(Buac et al., 2013).
These preliminary findings support the hypothesis that BCA2 protein expression may be
regulating the expression of NMNAT1 protein expression. Further, the preliminary data also
suggests that BCA2 might have a role in the regulation of cellular energy metabolism in cancer
cells because of the established role of glucose concentration on Warburg metabolism and
metastatic transformation. In order to investigate these hypotheses, a systematic evaluation of the
role of BCA2 in the regelation of NMNAT1 was performed utilizing stable shRNAs targeting
BCA2, NMNAT1, and BCA2/NMNAT1 combined. The model system was then used to examine
the effects of RNA inhibition on NMNAT1 protein, transcript, and promoter activity. In addition,
the model system was utilized to elucidate the effects of RNAi on Warburg-like metabolism, as
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defined by the expression of key markers of Warburg-like metabolism (LDHA/LDHB), Glucose
consumption, lactate production, and cellular proliferation.
shRNAi technology was utilized to stably and selectively knockdown the expression of
BCA2, or NMNAT1, or BCA2/NMNAT1 together. By comparing the effects of these types of
knockdown cell lines, it was possible to determine the specific and individual effects of BCA2 and
NMNAT1 expression on glycolytic metabolism, as well as the consequences on glucose
consumption and lactate production. By analyzing the different protein expression profiles in a
panel of glycolytic enzymes, as well as observing both glucose consumption and lactate production
in the three disparate shRNAi cell-lines (shBCA2-KD, shNMNAT1-KD, shBCA2/NMNAT1double knockdown (dKD), it was possible to discriminate the key glycolytic enzymes that were
associated with specific glucose metabolic activities and pathways. The proposed model system
for the effects of BCA2 on Warburg-like lactate metabolism is illustrated in Figure 1.6.
1.10 Propose model system for investigating the role of BCA2 and NMNAT1 in regulation
of Warburg-like metabolism and tumor progression.
BCA2 is known to inhibit AMPK activation. In addition, the literature suggests that
increased glucose concentrations can inhibit AMPK activation, which could be a potential
mechanism by which glucose modulates BCA2 expression and modulates aerobic versus anaerobic
metabolism in cancer cells. BCA2 protein expression is increased when AMPK is activated
pharmacologically. This suggests that BCA2 may be regulated by cellular energy status or may
regulate cellular energy homeostasis. The preliminary data already identified an inverse correlation
between BCA2 and NMANT1 in TNBCs by both the phospho-peptide enrichment mass spec data,
and by an analysis of published relative transcript levels provided by the Broad Institute CCLE
database.
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Proposed Model for Effects of BCA2 on Warburg-like Metabolism
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Figure 1.6: Proposed model for effects of BCA2 on Warburg-like metabolism.
The preliminary data supports an indirect role for BCA2 in the regulation of AMPK, the master
regulator of cellular energy homeostasis. BCA2 inhibits AMPK phosphorylation either indirectly
through modulating the cells energy (ATP/AMP) or by regulating the degradation, activation, or
localization of some intermediary protein or transcription factors that shift the cell’s energy
homeostasis towards anaerobic metabolism and tumor progression. This model proposes that
inhibition of BCA2 will increase NMNAT1 expression, which increases cellular NAD+, driving
the cell towards aerobic metabolism through the entry of pyruvate into the TCA cycle and resulting
in tumor inhibition. Conversely, if NMNAT1 is inhibited, the model proposes that the effect would
be to enhance the Warburg-like metabolism.
Based on the above data, the proposed model system will be used to investigate the
relationship between BCA2 and NMANT1 expression at the levels of protein (Western Blot),
transcript (rtPCR and qPCR), and promoter activity (Promega dual firefly luciferase assay).
shRNA technology will be used to selectively knockdown expression of BCA2, NMNAT1, and
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BCA2/NMNAT1, respectively. We will characterize the effects of stable shRNAi-KD of the
targets on key markers of Warburg-like metabolism (LDHA/LDHB), as well as evaluating the
downstream functional consequences on functional activities of the cancer cells, such as glucose
consumption, lactate production and relative proliferation rates.
The proposed model system suggests that BCA2 inhibits expression of NMNAT1 and vice
versa. Hence, decreased expression of the oncogene BCA2 would remove the constraints that the
tumor suppressor NMNAT1 would be exerting to repress Warburg-like metabolism and decrease
cellular proliferation rates. If the effects of shBCA2-KD on tumor progression and Warburg-like
metabolism are dependent on NMNAT1, then subsequent inhibition of NMNAT1 by shNMNAT1KD would reverse the effects observed in the shBCA2-KD clones alone.
This model proposes that the effects associated with BCA2 expression would be decreased
NMNT1, increased LDHA/LDHB, increased glucose consumption, increased lactate production,
and increased cell proliferation. If the Warburg-like effects associated with BCA2 are being
exerted through NMNAT1 or are dependent on an NMNAT1 dependent intermediate, then
knocking down NMNAT1 in the shBCA2 clonal populations should rescue the original aggressive
Warburg-like metabolic state. BCA2 is highly expressed in breast cancer cells and is relatively
low in normal tissues. In addition, Warburg metabolism is a fundamental and essential hallmark
of cancer. If it could be inhibited selectively in cancer cells by targeting BCA2, this would offer a
promising therapeutic target.
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CHAPTER 2: EXPERIMENTAL DESIGN, AND STATISTICAL ANALYSIS
2.1

Experimental design and controls
In order to investigate the role of BCA2 and NMNAT1 in the regulation of Warburg-like

metabolism and tumor cell proliferation, shRNAi stable knockdowns of the target transcripts were
used to modulate the expression of these two genes within the context of TNBC cell lines. TNBC
cell lines were used as the model system because the preliminary investigations were performed
in these cell lines, providing the foundation for an investigation into the correlation between BCA2
and NMNAT1. In addition, estrogen is known to play a regulatory role in BCA2 expression and
protein cycling (Kona, 2012). This could complicate the interpretation of the data because of the
diverse role that estrogen plays in the regulation of cellular metabolic activities.
Dr. Jian Wang identified NMNAT1 from mass spectrometry analysis data in an experiment
performed by Dr. Buac-Ventro in the Dou lab. The data was analyzed and interpreted in
collaboration with Dr. Caruthers of the Proteomics Core and revealed experimental evidence
linking BCA2 and NMNAT1 expression. In order to support the experimental data, the correlation
between BCA2 and NMNAT1 transcripts were analyzed using the Broad Institute’s CCLE
database, which also revealed that there was an inverse correlation between BCA2 and NMNAT1
transcripts when the breast cancer cell lines were sorted for TNBCs.
The proposed model for the effects of BCA2 and NMNAT1 on Warburg-like metabolism
hypothesizes that the mechanism of action is through the influence of NMNAT1 on the ratio of
NAD+/NADH in the nucleus. It is further hypothesized that the increase in the ratio of
LDHA/LDHB is modulated in response to the shift in NAD+/NADH in the nucleus resulting in
transcriptional changes increasing LDHA and decreasing LDHB translation (Figure 1.6). The
relationship between BCA2 and NMNAT1 and Warburg-like metabolism was unknown. It was
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unclear whether cross regulation between BCA2 and NMNAT1 plays a role in the regulation of
Warburg-like metabolism.
To investigate the roles of BCA2 and NMNAT1 in the regulation of Warburg-like
metabolism, an shRNAi model system was utilized to target: BCA2, NMNAT1, and
BCA2/NMNAT1 combined. In order to generate the dKD, two distinct shRNA-KD plasmid of
vectors were utilized. shBCA2-KD plasmid stocks were generated using stock vectors from the
pLKO plasmid construct library of TRC validated shBCA2 sequences (Vector control for
shBCA2-KD was shNon-Targeting-1 shNT1). shNMNAT1-KD plasmids were generated from
stock vectors from the pGIPZ construct library of TRC validated shNMNAT1 sequences (Vector
control for shNMNAT1-KD was shNon-Targeting-2 shNT2).
The protocols for the generation of a stable knockdown clonal population required multiple
transductions approaches. In the preliminary experiments, Sigma’s Mission lenti-viral packaging
kit was used to generate lentiviral particles with different shBCA2-KD vectors (a minimum of
three targeted sequences were used per cell line and gene to generate stable cell lines). This same
approach was used for the generation of stable shNMNAT1-KD clonal populations. However, to
generate the stable dKD, this lentiviral technique failed, and serial transfections of the
shNMNAT1-KD plasmids were necessary to achieve stable shBCA2/NMNAT1-dKD.
To generate dKD clonal populations of TNBCs, serial transfection with the Muris LT1
system every 48 hours for 3 successive treatments with selection in-between each cycle of
transfections was performed. This was necessary because the cells already had the pLKO vector
in it, so antibiotic selections by puromycin (PUR) alone would not work.
The pGIPZ construct contained the reporter protein GFP, which allowed serial dilution in
a 96 well plate for expanding only the clonal populations that had single colonies. Upon expansion
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and continued selection, clonal populations still retained GFP expression. At this point, western
blots were run, and the clonal populations were identified with stable shBCA2/NMNAT1-dKD
relative to the control (shNT2). Stable cell lines were necessary for running the remaining
experiments because of the time scale needed to carry out the media analysis and proliferation
assays, respectfully.
The controls for the experimental model were required to assess for off-target effects of
the shRNAi system. To generate the shBCA2/NMNAT1-dKD, two different plasmid constructs
(one for each gene) were used. As important as it was to control for the rigorous selection process,
it was equally important to comply with the transfection protocol to obtain stable
shBCA2/NMNAT1-dKDs. The dual vector system required the generation and validation of
multiple non-targeting control clonal-populations of cells to provide both vector controls (shNT1pLKO and shNT2-pGIPZ) and the clonal selection needed to generate the dKD. The first step was
to identify the system controls and then ensure there were no off-target effects created by their
integration. Controls included the parental lines for each cell line (Pr), the shBCA2 control
(shNT1), the shNMNAT1 control (shNT2), and the shBCA2/NMNAT1 control (shNT1/2).
Experiments were performed with the key controls for each system being investigated and
displayed in the corresponding figures below. Additional experiments were performed at the start
of each new phase of genetic manipulation to confirm that the control vectors matched the activity
and expression profiles of the Pr lines and that the different control vectors all acted the same
within the context of the experimental model. These results set the baseline for the remaining
experiments to evaluate the effects of shBCA2-KD, shNMANT1-KD, and shBCA2/NMNAT1dKD in the model system.
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2.2

Scientific rigor and statistical analysis
Western blot analysis of the relative protein expression was performed utilizing the

ChemiDoc XRS digital imaging platform software analysis. Image J was used to collect relative
band intensity values for each western blot. Densitometry and statistical analysis of the
experimental model were used to determine the significance of the research findings. In order to
ensure the validity of the results, the following practices were used for all experiments (except
where noted otherwise). The following preliminary experiments were performed to validate the
system before the results were processed and calculated.
Glucose concentration is a well-established modulator of AMPK activation, the
preliminary investigation into the project examined the effects of glucose concentration on AMPK
activation (Molina et al., 2014). The change in AMPK activation in response to glucose could have
been due to either depletion of glucose levels (low cellular energy status) or the result of the
buildup of some secondary metabolite, which regulates AMPK through some other pathway.
Therefore, it was essential that the experimental conditions, including glucose concentration, cell
confluence, and time in media, were carefully controlled.
The following experimental parameters were established for data collection and for
statistical analysis of the results: (a) experiments using media containing high glucose media, (b)
cells were not allowed to reach confluence (cells were seeded at ~<60%, and harvested within 24
hours of seeding), (c) cells were not left in the same media for longer than 36 hours. Exceeding
these parameters resulted in changes in cell morphology, loss of cell adhesion, changes in marker
metabolism (protein and transcript), changes in functional measures of metabolism (glucose
consumption and lactate production), and cell behavior (proliferation).
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A minimum of three independent experiments were performed for each series of
experiments (glucose, shBCA2, shNMNAT1, and shBCA2/NMNAT1), and representative
western blots were displayed. Replicate images from a minimum of three independent experiments
were analyzed by Image-J, and densitometry was performed. The densitometry data were
normalized to the housekeeping gene (-actin) and then normalized to the corresponding vector
control. Results were displayed in bar graphs as (% Arbitrary Units (AUs) (normalized to -actin)).
As previously mentioned, corresponding control vectors were used for each targeting vector. These
controls were previously validated against each other to evaluate any off-target effects of the
controls in the model system.
Error bars were calculated by mean ± SEM (Standard Error Mean +/-) in the experiments,
with triplicate experiments performed on separate days. Statistical analysis used a two-tailed
student t-test with a p-value tolerance of < 0.05. Asterisks (*) were used to indicate data that were
statistically significant based on the stated criteria. All analyses were performed in Microsoft Excel
and were reviewed by Dr. Seongho Kim of Wayne State University.
2.3

Materials and methods

2.3.1 Reagents
Multiple primary and secondary antibodies were used in this study. Anti-BCA2 antibody
(anti-ZNF364 antibody [EPR14539] (ab187642)) and LDHB antibody ([EP1565Y] LDHB rabbit
mAb) were obtained from AbCam (Cambridge, MA). LDHA ((C4B5) rabbit mAb (#3582))
antibody came as a component of the glycolysis antibody sampler kit #8337 from Cell Signaling
Technologies (Danvers, MA). NMNAT1 antibody ((B-7): sc-271557) was obtained from Santa
Cruz Biotechnology Inc. (Dallas, TX.). Finally, anti--actin antibody ([AC-15] (ab49900)),
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG, and anti-mouse IgG secondary
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antibodies were obtained from Sigma-Aldrich Corp (St. Louis, MO). All primary antibodies were
stored at -20ºC and secondary antibodies at 4ºC in compliance with the manufacturer’s
instructions.
2.3.2 shRNA vectors and constructs
Short hairpin RNA (shRNA) sequences were purchased from Sigma-Aldrich Corp (St.
Louis, MO). Three BCA2 targeted shRNA pLKO constructs included the clone IDs and their
corresponding sequences: sh21: TRCN0000433273; sh22: TRCN0000416451; and sh23:
TRCN0000004393. The shRNA clones targeted the following locations (sh21(3’UTR),
sh22(CDS), and sh23(CDS). Additional shRNA clones targeted to NMNAT1 were purchased from
Invitrogen in the pGIPZ constructs with the following clone IDs, sh73 V3LHS_315167, sh74:
V2LHS_98547, and sh75: V2LHS_98548.
The shRNA constructs were provided in 5hα-E.coli stabs. E. coli stocks were expanded in
selection media, and frozen aliquots were stored in -80o C. The E.coli stocks were clonally selected
and expanded in luria broth from Invitrogen, (Carlsbad, CA), then the plasmids containing the
shRNA constructs were isolated with a Qiagen (Valencia, CA) mini prep kit. Purified plasmids
were measured with a Nano-drop (Thermo Scientific). Stocks were stored at -20ºC in TE (Tris and
EDTA) buffer before transfection into breast cancer cell lines for validation of the knockdown
efficiency of the specific shRNA sequences. Non-silencing control shRNA (shNT:sh61) was used
as a negative control as this was a non-specific scrambled sequence, designed not to target any
mRNA sequences. Validation of the individual shRNA’s knockdown efficiencies was assessed by
western blots and PCR analysis. Subsequent western blots were run to determine if there were any
off-target effects of the shRNAs. After the sequences were validated, the purified plasmids were
packaged into lentiviral particles using Sigma’s Mission lentiviral packaging kit (Sigma, Cat #:
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SHP002), following their protocol for packaging and titration. Following lentiviral transductions,
clonal populations were obtained by serial dilution in 96-well plates. Six clones were selected for
each plasmid (sh-NT1, -NT2, -BCA2, & -NMNAT1), expanded and validated as with the
transfection system.
dKD clonal populations were obtained by serial transfection of the validated shNMNAT1
plasmids into the shBCA2-KD clonal populations. Transfections were repeated every 48 hours for
8 days (4 treatments), after which transfection selection media was applied and the cells were
observed for Green Fluorescent Protein (GFP) expression. The pLKO (shBCA2) plasmid vectors
did not contain GFP reporter protein, while the pGIPZ (shNMNAT1) plasmid vectors did contain
the GFP reporter protein. Therefore, cells that expressed GFP in the shBCA2 background would
be dKD populations (shBCA2/NMNAT1). The dKD cells were observed under the microscope
until they reached 80% confluence, at which point they were trypsinized and sorted for GFP
expression, expanded and validated for knockdown efficiency and off-target effects as in the
previous model systems.
2.3.3 Cell culture
Human breast cancer cell lines (MDA-MB-468 & MDA-MB-231) and embryonic kidney
fibroblast (HEK293T) cells were obtained from the American Type Culture Collection (Manassas,
VA). MDA-MB-468 and MDA-MB-231 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Invitrogen, Carlsbad, CA) containing 10% Hyclone Fetal Bovine Serum (FBS)
(Fisher Scientific, Pittsburgh, PA), 100 µg/ml streptomycin, and 100 units/ml penicillin
(Invitrogen, Carlsbad, CA). Further, HEK293T cells were grown in antibiotic free DMEM
containing 10% FBS. Cells were maintained at 37°C and 5% CO2 and passaged routinely upon
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approaching 80% confluence. Glucose was obtained from Invitrogen (Carlsbad, CA) and used to
supplement the DMEM as stock according to experimental conditions.
2.3.4 Generation of stable shRNA clones
Exponentially growing MDA-MB-468 and MDA-MB-231 cells were plated at 40-50%
confluency in 6-well plates and allowed to adhere overnight. The next day, media containing 1%
FBS was added in place of the 10% FBS, prior to transfection with shRNA plasmid constructs.
Transfections were performed utilizing Lipofectamine® LTX reagent according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA), with shNT non-targeting shRNA vector as a
control. Following a 48-hour incubation period, cells were selected via puromycin (PUR)
antibiotic selection, according to the empirically derived kill curves for each cell line. Stably
transfected cells (2-3 weeks of PUR selection) were subsequently expanded by serial dilution to
obtain clonal populations. Expanded samples were harvested and lysed for western blot analysis
to determine the clones with the most efficient shBCA2-KD.
Co-transfection experiments were performed by serial transduction of the second shRNA
(shNMNAT1) vectors into stably selected shBCA2, and shNT (control) clonal cell lines. The
shNMNAT1 vectors contained GFP expression vectors, which allowed for the flow cytometry
selection of clonal populations of cells that expressed both shBCA2 and shNMNAT1-KD vectors.
The knockdown of NMNAT1 was confirmed by western blot analysis, once populations were
sufficiently expanded. Transfections were performed using Mirus TransIT®-LT1 transfection
reagent (Cat # MIR 2305A; Madison, WI) following the manufacturer’s protocol. MDA-MB-468
and MDA-MB-231 breast cancer cells were plated in 60-mm dishes at 60% confluency and
allowed to seed overnight. Fresh media without antibiotics, was applied two hours prior to
transfection. Transfection reagent/DNA complex was formed with a ratio of 3 μl per LT1/ 1 μg
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plasmid DNA and applied to the cells according the manufacturer’s protocol. After 48 hours, cells
were treated as indicated, then were expanded for validation, and frozen aliquots were stored after
two weeks in selection media. Cells were harvested and lysed for analysis by western blotting to
assess their initial knockdown efficiency. The best clones were expanded and selected for stable
dKD after serial dilution.
2.3.5 Western blotting
The cell lines were transfected, glucose treated, or stably selected before harvesting. Cell
lysates (30-40 µg) were mixed with 3X sodium dodecyl sulfate (SDS) buffer and boiled for 5
minutes. They were then analyzed by SDS-polyacrylamide gel electrophoresis using 12% trisglycine gels (Invitrogen, Carlsbad, CA). Cells were then transferred to polyvinylidene difluoride
(PVDF) membranes (Millipore, Billerica, MA), and blocked in 3% blocking buffer (3% non-fat
dry milk) in tris-buffered saline, 0.1% tween ® 20 detergent (TBST) at room temperature for one
hour. The primary antibodies were diluted in blocking buffer (1:1000) and incubated overnight at
4°C on a rocker. Membranes were washed in TBST and incubated with species-specific secondary
antibodies conjugated to HRP (1:10,000) for two hours at room temperature. Signals were
developed with Pierce [Picco or Fempto] super signal chemiluminescent ECL reagent (Thermos
scientific, CA.) and then imaged using the BioRad ChemiDoc XRS+ imaging system with Image
Lab Software (BioRad, CA.). Densitometry analysis was performed using Image Lab software
(LICOR Biosciences) to determine relative intensity calculated as a percentage of the loading
control (-actin).
A minimum of three independent experiments were performed for each series of
experiments (glucose, shBCA2, shNMNAT1, and shBCA2/NMNAT1). Representative western
blots are displayed. Western blot images were analyzed by Image-J, and densitometry was
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performed on a minimum of three independent replicate experiments. The densitometry data were
normalized to the housekeeping gene (-actin) and then normalized to the corresponding control
vector. The results were displayed in bar graphs as (%AUs) (normalized to -actin). As previously
mentioned, corresponding control vectors were used for each targeting vector. These controls were
previously validated against each other to evaluate any off-target effects of the controls in the
model system.
2.3.6 Cell proliferation assays
In order to determine the relative proliferation rates of the dipartite shRNAi-KD clonal cell
lines, the Beckman Coulter particle counter (Indianapolis, IN.) was used to assess the number of
cells present under each condition over a period of six days. Cells were plated in a six-well plates
in equal amounts (10,000 cells/well). After counting the number of cells in each sample condition
over a period of six days, Excel (Microsoft) was used to determine the relative proliferation rates
relative to the shNT-control.
2.3.7 mRNA transcript analysis by qPCR and rtPCR with DNA-gel
A RNeasy Mini Kit (QIAGEN) was used to extract the total RNAs. RNAs were reverse
transcribed into complementary DNAs using iScript a cDNA synthesis kit (New England Biolabs).
cDNA

amplification

primer

pairs

for

BCA2

were

as

follows:

forward,

5′-

GGGGTCACCAGACTCACACT-3′; and reverse 3′-CAGGAAAAAGGGTGTGGAGA-5′. For
NMNAT1, primers were forward 5’-GAGCGCGGCTACAGCTT-3’; and reverse 3’TCCTTAATGTCACGCACGATTT-5’.

-actin

was

amplified

(forward

5’-

GAGCGCGGCTACAGCTT-3’ and reverse 5’-TCCTTAATGTCACGCACGATTT-3’) and used
for normalization. A Qiagen qPCR analysis machine was used to perform the qPCR analysis, and
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to expand the cDNA sequences for gel agarose analysis (rtPCR). cDNA fragments amplified for
rtPCR analysis were run on a DNA-agarose gel with ethidium bromide and imaged on BioRad
ChemiDoc XRS+ Imaging System. The images were then analyzed by Image-J. Relative signal
intensity was normalized to the housekeeping gene -actin, and values were presented as % AU
normalized to the control.
2.3.8 NMNAT1 promoter luciferase assay
Cells were plated in 96-well plates and co-transfected with the NMNAT1 promoter–
luciferase vector (pLightSwitch_Prom: Product # S705857; Switch Gear Genomics; Carlsbad,
CA) and a Renilla vector from Promega (Madison, WI), according to Switch Gear Genomics Light
Switch Luciferase Assay System. Stable shBCA2-KD cells were plated in both 96-well plates and
six-cm dishes for parallel evaluation of protein expression and confirmation of shBCA2-KD. The
effects of shBCA2-KD on NMNAT1 promoter activity were calculated as Relative Luciferase
Units (RLU) relative to the control Renilla vector. The experiment was repeated twice under high
glucose conditions overnight. The results presented represent two experiments performed in
triplicate in high glucose (4.5 g/l) media.
2.3.9 Proteomics
Dr. Carruthers and Dr. Caruso of the Wayne State University Proteomics Core assisted
with protein analysis. Protein and base peptides were identified via MS/MS analysis and validated
using Scaffold version _4.1.1, Proteome Software Inc. (Portland, OR). Per the Peptide Prophet
algorithm, peptides identified at greater than 80% were acknowledged (Keller, Nesvizhskii,
Kolker, & Aebersold, 2002) with scaffold delta-mass correction and were accepted if they
contained at least one identified peptide. Then, protein probabilities were assigned (Nesvizhskii,
Keller, Kolker, & Aebersold, 2003). Proteins that could not be identified during the analysis were
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either grouped into clusters based on peptide evidence or grouped using the principle of parsimony.
Significant peptides were grouped into clusters (courtesy of Dr. Paul Stemmer & Dr. Daniela
Buac-Ventro) and plotted into a venn diagram.
2.3.10 Media analysis
All reagents and procedures for the media analyses were generously provided by and
performed by Dr. Jian Wang’s lab. Experimental conditions and sample preparation were
performed in the Dou lab. For the media analysis, all vectors were carried out in triplicate with
two independent time points for sample collections. The experiments were repeated with refined
experimental parameters, two additional times for each vector, and each cell line used. Cells were
plated at 60% confluence in 60 mm2 plates the day before treatment and allowed to seed in normal
media. At time zero hours, media was replaced with fresh media, and the initial glucose sample
was collected. The initial experiments examined the changes in media glucose and lactate levels
over periods of 12, 24, and 48 hours. The preliminary experiments revealed no difference in
glucose consumption or lactate production at 24 and 48 hours. It was determined that the cells
were depleting all the available glucose in the media at earlier time points. In order to assess the
effects of shBCA2, shNMANT1, and shBCA2/NMNAT1 earlier time points would need to be
evaluated. Subsequent experiments narrowed the optimum time to 12 hours. Preliminary
experiments also evaluated whether there were functional differences in glucose consumption or
lactate production between the parental (Pr) and the non-targeting controls to determine if there
were any off-target effects associated with shRNA insertion or clonal selection. No difference was
observed between Pr and non-targeting vectors in proliferation rates or media composition. All
graphs and data presented are for 12 hours incubation, with three samples run for each of the
conditions, and two independent experiment dates to demonstrate reproducibility. Graphs
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represent the statistical average percent change in glucose consumption or lactate production
relative to the non-targeting control vector (shNT).
2.3.11 Glucose consumption assay
Glucose consumption in the model system was determined by an enzyme-linked assay that
compared the initial concertation of glucose at time zero hour (time zero was defined at the moment
media was changed the following day after cells were seeded) in the media, relative to the endpoint
concentration of glucose in the media, corrected for the number of cells in the plate. The relative
glucose consumption was calculated in % Relative Glucose Consumption Normalized to Control.
Relative glucose consumption was assessed relative to the shNT control vector specific to the
target construct (shBCA2=shNT1, shNMNAT1=shNT2, and shBCA2/NMNAT1=NT1/NT2:
shNT2 in the figures and in the text).
All reagents were obtained from Sigma-Aldrich (Sigma, St. Louis, MO) including:
Hexokinase/Glucose-6-Phosphate Dehydrogenase (HK/G6PDH) (Sigma, H8629), ATP (Sigma,
A2383), NADP+ (Sigma, N5755), MgCl2 (Sigma, M8233), tris base (Fisher, BP152-5), and
glucose (Sigma, G7528). The assays were run in a Costar 96-well plate (Costar, 3635) and read by
CLARIOstar microplate reader (BGM LABTECH). Media control and stock glucose
concentrations were used to establish a standard curve, and the number of cells per well were
counted by Beckman Coulter particle counter (Beckman Coulter, Pasadena, CA) (as described
previously in the proliferation assay section).
The glucose consumption assay developed and carried out by Dr. Jian Wang’s lab was
based on an enzyme coupled reduction assay. The assay works by coupling the phosphorylation
of the available glucose in the media by HK with ATP, which yields proportional Glucose-6Phosphate (G6P) and ADP (equation 1).
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(1)
G6P is then oxidized by glucose-6-phosphate dehydrogenase in the presence of NADP+ to
produce 6-phosphogluconolactone while concomitantly reducing NADP+ to NADPH, which gives
off an absorbance at 340 nm. The intensity of the absorbance measured at 340 nm is proportional
to the glucose concentration in the sample (equation 2).

(2)
In order to determine the actual concentration of glucose, a standard curve with serial
dilutions of glucose with the following concentrations was used: 0, 0.156, 0.3125, 0.625, 1.25, 2.5,
and 5 mg/ml. The assay mix was prepared with the following components: 25 mM tris-HCL pH
8.0, 1 mM MgCl2, 1 mM NADP+, 1 mM ATP, and 2 units/ml HK/G6PDH. Two l of standard or
sample were added to each well of the assay plate followed by 100 l assay mix to each well. The
assay plate was then incubated at room temperature for 30 minutes.
After the 30-minute incubation period, absorbance was measured at 340 nm and compared
against the reagent blank (sample media at time zero hour) on the CLARIOstar microplate reader.
Glucose standards were plotted and used to interpolate the sample glucose concentrations. The end
glucose concentration was subtracted from the beginning concentration and corrected for the
number of cells in each plate, determined by cell counting using the Beckman Coulter particle
counter, as described in the proliferation assays.
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2.3.12 Lactate production assay
Lactate production in the model system was determined by an enzyme linked (LDH) assay
that compared the initial concertation of lactate at time zero hour in the media, relative to the
endpoint concentration of lactate in the media, corrected for the number of cells in the plate. The
relative lactate production was calculated in % Relative Lactate production Normalized to Control.
Relative lactate production was assessed relative to the shNT control clonal population of cells.
All reagents for the assay were obtained by Dr. Jian Wang’s lab from Sigma-Aldrich
(Sigma, St. Louis, MO) including: LDH (Sigma, L3916), NAD+ (Sigma, N0632), Hydrazine
(Sigma, 215155), Tris Base (Fisher, BP152-5), Bovine Serum Albumin (BSA) (Sigma, A7906)
and lactate (Sigma, L7022). The assays were performed and read in a Costar 96-Well plate (Costar,
3635) and read by a CLARIOstar microplate reader (BGM LABTECH). Media controls and stock
glucose concentrations were used to establish a standard curve, and a number of cells per well
were counted by Beckman Coulter particle counter (Beckman Coulter, Pasadena, CA), as
described previously in the proliferation assay section.
The lactate production assay was developed and carried out by Dr. Jian Wang’s lab and is
based on the enzyme (LDH) linked coupling of the oxidation of lactate to pyruvate, and the
concurrent reduction of NAD+ to NADH which can be measured the by the intensity of absorbance
at 340 nm (equation 3).

(3)
The intensity of this absorbance was proportional to the concentration of lactate in the
sample. Hydrazine drives the complete conversion and removal of pyruvate from the reaction,
drawing the equilibrium of the combined reactions to consume all the lactate present in the sample

48
(equation 4). By driving the reaction to use up the lactate in the reaction completely, the absorbance
measured at 340 nm is proportional to the concentration of lactate present in the sample.

(4)
Comparing the concentrations of lactate at time zero hour and 12 hour and correcting for
the number of cells in the plate allowed for the calculation of the nmoles lactate produced / 10^6
cells. This value was then normalized to the control condition as 100% and the data were
interpreted as % lactate production relative to the non-targeted controls.
To determine the amount of lactate produced in each condition, serially diluted lactate
reference standards were used to generate a standard curve and convert absorbance at 340 nm to
nmoles lactate. The following reference standards were used: 0nM, 30nM, 100nM, 300nM, 1,000
nM of lactate. Once the samples were collected and cell counts were determined, the sample assay
mix was prepared with the following components: (a) 320 mM tris-HCL pH 9.0, (b) 320 mM
hydrazine, (c) 4 mM NAD+, (d) 1% BSA, and (e) 16 units/ml LDH. Fifty l of sample and
standards were added to each well of the assay plate, then 50 l assay mix was added to each well
and left to incubate at room temperature for 30 minutes.
Two ls of standard or sample are added to each well of the assay plate followed by 100
ls assay mix to each well. The assay plate was then incubated at room temperature for 30 minutes.
After the 30 min incubation period, absorbance was measured at 340nm on the CLARIOstar
microplate reader and compared against the reagent blank (sample media at time zero hour).
Lactate standards were plotted and used to interpolate the sample lactate concentrations.
The initial lactate concentration was subtracted from the end concentration and corrected for the
number of cells in each plate, as determined by cell counting using the Beckman Coulter particle
counter.
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CHAPTER 3: CORRELATION BETWEEN BCA2 AND NMNAT1
A Kaplan Meyer analysis was conducted in a prior study of BCA2 relative to patient
survival. The Kaplan Meyer analysis identified BCA2 as an oncogene (Buac et al., 2013). High
BCA2 expression is associated with a lower overall survival probability relative to low BCA2
expression (Burger et al., 2010). Although not statistically significant, the analysis conducted by
Dr. Jian Wang provided a p-value of 0.061, just over the statistically significant threshold. In
addition, NMNAT1 is a known tumor suppressor (Henderson, Miranda, & Emerson, 2017).
3.1

Prior research and preliminary evidence for inverse relationship between BCA2 and
NMNAT1
Based on these findings, a transcript analysis was performed to examine the association

between BCA2 and NMNAT1 expression in TNBC cell lines. The analysis measured mRNA
expression normalized to β-actin and suggested an inverse correlation between BCA2 and
NMNAT1 transcript levels (Figure 3.1). Data (mRNA Expression (RNAseq) obtained from the
Broad Institute for both BCA2 and NMNAT1 were segregated by TNBC cell lines and plotted on
a dot plot, and the spearman correlation determined. The relative BCA2 and NMNAT1 transcripts
normalized to β-actin revealed an inverse correlation (Figure 3.1). The calculated spearman’s
correlation was -0.86. Along with the preliminary phosphoproteomic data from Dr. Buac-Ventro,
these results provided additional rationale to investigate the association between BCA2 and
NMNAT1 in TNBC.
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Figure 3.1 BCA2 and NMNAT1 transcript expression are inversely correlated in triple
negative breast cancer cell lines
In-Silico Analysis of CCLE Database Expression Correlation Between BCA2 and
NMNAT1 Transcript Expression in Triple Negative Breast Cancer Cell Lines
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mRNA Expression (RNAseq): NMNAT1
The relative expression of the BCA2 and NMNAT1 transcripts were plotted from data obtained
from the Broad Institute’s (CCLE) transcript database. The relative transcript expression (mRNA
Expression (RNAseq)) normalized to Actin for BCA2 and NMNAT1 in TNBC cell lines was
plotted, and statistical analysis performed. The graph revealed an inverse correlation between
BCA2 and NMNAT1 in the TNBC cell lines. The spearman’s correlation between BCA2 and
NMNAT1 in the TNBC cell lines was -0.86. These data provided the rationale to investigate the
association between BCA2 and NMNAT1 in TNBC.
3.2

Glucose stimulation increased BCA2 and decreased NMANT1 protein expression
A study was conducted to ascertain the effects of glucose concentration on BCA2 and

NMNAT, respectively. Western blots were run where glucose was either added in excess or was
deprived in two TNBC cell lines (MDA-MB-468 and MDA-MB-231). Initial glucose deprivation
was performed overnight for both TNBC cell lines, resulting in the absence of BCA2 and the
presence of NMNAT1 protein expression at zero hour, followed by eight hours of glucose added
in excess. Densitometry was performed and results are expressed as % AUs normalized to β-actin
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and are reported as mean values for a minimum of two representative blots performed on separate
dates. Standard errors were included when triplicate experiments were available. Representative
western blots are shown for each graph (Figure 3.2).
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Figure 3.2 Glucose concentration is positively
correlated with BCA2 protein expression,
-bactinand inversely correlated with NMNAT1 protein expression.
BCA2 protein expression is positively correlated with glucose concentration, as demonstrated in
the representative western blots of MDA-MB-468 and MDA-MB-231. A. Western blot of
TNBCSLs treated with increasing concentrations of glucose (after glucose starvation overnight)
for 16 hours. B. Densitometry data showed that glucose stimulated BCA2 in TNBC cell lines
increased, with BCA2 protein increased by ~500% at the maximum concentration of glucose in
both cell lines. This was accompanied by a decrease in NMNAT1 protein expression in response
to glucose stimulation (MDA-468 ~73%; and MDA-231 ~13%). These results show that BCA2
and NMANT1 protein expression is inversely correlated in response to glucose stimulation.
3.3

Glucose deprivation decreased BCA2 and increased NMANT1 protein expression
Figure 3.3 illustrates the effects of glucose deprivation of both TNBC cell lines on BCA2

protein. BCA2 expression was detected at zero hours (lane one) and progressively decreased,
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resulting in a complete loss of BCA2 protein expression at 16 hours (lane five). In both breast
cancer cell lines, a direct correlation between the presence or absence of glucose with BCA2 was
found. There was an inverse relationship between BCA2 and NMNAT1. At eight hours, both cell
lines showed an increase in NMNAT1 expression of ~200%, with a corresponding 51-65%
decrease in BCA2 protein expression. The glucose stimulation and deprivation experiments were
repeated at least three independent times, and representative images from a single experiment are
shown along with the corresponding densitometry data that shows the average changes in protein
expression in the given conditions.
3.4

Discussion
These data suggest that an inverse relationship between BCA2 and NMNAT1 expression

exists in relation to extracellular glucose concentrations. These data in conjunction with prior
research findings, substantiate the inverse correlation previously reported between BCA2 and
NMNAT1 (Buac et al., 2013). These data show that the effects of glucose concentration on BCA2
and NMNAT1 protein expression support the hypothesis that NMNAT1 may be a potential target
protein of BCA2 either directly or indirectly. Further, these data support the CCLE in-silico
analysis and the MS/MS data. Finally, these data signify a need for further investigation into the
relationships between BCA2 and NMNAT1 expression in TNBC cell lines, as well as a need to
explore further the mechanism by which glucose levels affect the expression of both proteins.
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Glucose Deprivation Results in Decreased BCA2 and Increased NMNAT1 Protein Expression
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Figure 3.3 Glucose deprivation is associated with decreased BCA2 protein expression, and
increased NMNAT1 protein expression
To determine if the inverse association between BCA2/NMNAT1 occurs in response to glucose,
a glucose deprivation assay was performed. Cells were plated in normal media and allowed to sit
overnight. A. Results are shown that illustrate the effects of glucose deprivation in both TNBC cell
lines (MDA-MB-468 and MDA-MB-231) from 0 to 16 hours. B. The graphs show the
densitometry for the relative protein expression normalized to Actin. The results indicate that
glucose deprivation results in a time-dependent decrease in BCA2 protein expression. In addition,
there is an inverse correlation between NMNAT1 protein expression relative to glucose
concentration concurrent with the changes in BCA2 protein expression. A minimum of 3 blots
were imaged from different passages and averaged for densitometry data; representative blots of
the results are shown. These results suggest an inducible inverse correlation between BCA2 and
NMNAT1, consistent with the preliminary Mass-Spec and in-silico analyses of BCA2 and
NMNAT1 in TNBC cell lines.
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CHAPTER 4: shBCA2-KD REGULATES NMNAT1 PROTEIN, TRANSCRIPT, AND
PROMOTER ACTIVITY
shRNAi technology was utilized to knockdown the expression of BCA2 through the
lentiviral transduction of multiple shBCA2 constructs into the TNBCs, MDA-MB-468 and MDAMB-231, following manufacturer’s protocol as described in the materials and methods section. A
minimum of three targeted shRNA sequences for BCA2 were transfected into each cell line. Serial
dilutions of the pooled populations of stably expressing shRNA vectors were used to generate
clonal populations of shBCA2-KD and were validated by western blot and PCR.
4.1

shBCA2-KD resulted in a significant decrease in BCA2 protein and resulted in a
corresponding increase in NMNAT1 expression.
shBCA2-KD by shRNA significantly decreased protein and transcript expression of

BCA2. Expression of BCA2 and NMNAT1 proteins were assessed via western blot analysis, and
densitometry analyses were performed to assess the relative expression of BCA2 and NMNAT1.
BCA2 protein expression significantly decreased in both MDA-MB-468 (54% and 49%) and
MDA-MB-231 (31% and 19%) (Figure 4.1).
In addition, the expression of NMNAT1 protein was increased MDA-MB-468 (147% and
216%) and MDA-MB-231 (394% and 604%) and inversely correlated with expression of BCA2
protein. Thus, shBCA2 genetic knockdown decreased BCA2 protein expression and resulted in an
increase in NMNAT1 protein expression (Figure 4.1)
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shRNA Knockdown (KD) of BCA2 Resulted in a Significant Decrease in
BCA2 Protein Expression, and an Inverse increase in NMNAT1 Protein Expression
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Figure 4.1
shRNA KD of BCA2 in MDA-MB-468 and MDA-MB-231 significantly
decreased BCA2 protein expression, associated with a concurrent increase in NMNAT1
protein expression.
Stable clonal populations of shBCA2-KD were achieved through lentiviral transduction of
multiple shBCA2 vectors, as well as a sh-Non-Targeting control (shNT), followed by clonal
selection, validation, and expansion. A minimum of 3 blots were imaged from different passages
and averaged for densitometry data. Representative blots are shown. The shNT control vector had
no effect on the expression of BCA2 or NMNAT1 protein expression. However, shBCA2-KD
resulted in a stable knockdown of BCA2 in both cell lines (MDA-MB-468: 54% and 49% and
MDA-MB-231: 31% and 19%), correlating with a robust increase in NMNAT1 protein expression
in both cell lines (MDA-MB-468: 147% and 216% and MDA-MB-231: 394% and 604%).
4.2

shBCA2-KD significantly decreased BCA2 transcript and increased NMNAT1
transcript expression.
The above findings validated the correlation between BCA2 and NMNAT1 at the protein

level and showed that this association was both inducible (in response to glucose) and could be
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achieved through genetic manipulations (shBCA2-KD). Under both stimuli BCA2 and NMNAT1
were inversely correlated.
In order to determine if shBCA2-KD was modulating NMNAT1 transcript expression
rtPCR (DNA-Gel), and qPCR were used to assess the fold change in NMNAT1 transcript. DNA
gels were performed in triplicate, and signal intensity was measured using Image-J. Densitometry
was normalized to the ß-actin housekeeping gene and the control vector shNT. shBCA2-KD
resulted in a significant decrease in BCA2 transcript expression in both cell lines (MDA-MB-468:
12%, MDA-MB-231: 6%). shBCA2-KD was accompanied by an increase in NMNAT1 transcript
expression (MDA-MB-468: 315%, MDA-MB-231: 854%) as determined by densitometry of the
corresponding western blot DNA-gels.
In order to verify the preliminary transcript data, qPCR analysis was performed in triplicate
with a Qiagen q-PCR kit on an Applied Biosystems™ StepOnePlus™ Real-Time PCR System.
Results are shown for relative mRNA expression normalized to ß-actin and NT Control (ΔΔCT).
shBCA2-KD resulted in significant decreases in BCA2 transcripts (MDA-468, 45%; MDA-231,
31%) and increased NMNAT1 transcripts (MDA-468, 146%; MDA-231, 150%). These data
suggest that BCA2 is somehow regulating the expression of NMNAT1 at the transcript level, as
well as at the protein level.

57

A.

Densitometry of DNA Gel analysis of rtPCR
samples MDA-MB-468

% AUs Normalized to bactin

B.
350%

250%
200%
150%
100%
100%
50%
0%
Probe:
Vector:

*

100%

12%
BCA2
shNT shBCA2

NMNAT1
shNT shBCA2

Densitometry of DNA Gel analysis of rtPCR
samples MDA-MB-231
1000%

*

854%

900%
800%
700%
600%
500%
400%

*

300%
200%

100%

100%

100%

6%

0%
Probe:

BC A2

Vector:

shNT

MDA-MB-231
200%

*

146%

150%

100%

100%

100%

*

*

45%

50%

Relative mRNA Expression Normalized to ßActin and NT
Control (ΔΔ CT)

200%

0%
Vector: shNT
Probe:

NMNAT1
shNT shBCA2

shBCA2

MDA-MB-468
Relative mRNA Expression Normalized to ßActin and NTControl (ΔΔCT)

C.

315%

300%

% AUs Normalized to bactin

shBCA2-KD Significantly Decreased Transcript Expression of BCA2 in both TNBC cell lines
and Increased the Expression of NMNAT1 Transcript by both Q-PCR or rt-PCR (DNA-gel) Analyses

*

150%
150%

100%

100%

100%

*

50%

31%

0%
shBCA2
BCA2

shNT

shBCA2
NMNAT1

Vector:
Probe:

shNT

shBCA2
BCA2

shNT

shBCA2
NMNAT1

Figure 4.2 shBCA2-KD significantly decreased BCA2 transcripts and increased NMNAT1
transcripts by rt-PCR (DNA-gel) and qPCR analyses in both TNBC cell lines.
shBCA2-KD resulted in decreased BCA2 transcripts and increased NMNAT1 transcripts in both
TNBCSLs (shBCA2-MDA-MB-468: 12% BCA2 and 315% NMNAT1 / shBCA2-MDA-MB-231:
6% BCA2 and 854% NMNAT1), as determined by analysis by rt-PCR and staining and
densitometry of a DNA gel. Densitometry was normalized to ßActin and the shNT. The
densitometry was performed on images from separate experiments done in triplicate. shBCA2 also
had similar effects when measured by qPCR analysis. Samples were run in separate experiments
in high glucose media and in triplicate. Values represent relative mRNA expression normalized to
ß-actin and NT Control (ΔΔCT). Results were as follows: shBCA2-MDA-MB-468: 12% BCA2
and 146% NMNAT1 / shBCA2-MDA-MB-231: 31% BCA2 and 150% NMNAT1. These data
suggest that BCA2 is regulating the expression of NMNAT1 at the transcript level as well as at
the protein level.
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4.3

shBCA2-KD significantly increased NMNAT1 promoter activity
The previous findings demonstrated that shBCA2-KD induces NMNAT1 protein and

transcript expression. Switch Gear Genomics Light Switch Luciferase promoter activity assay was
used in order to explore whether shBCA2-KD regulated changes in NMNAT1 at the level of
NMNAT1’s promoter. Cells were plated in 96-well plates and cotransfected with reporter vectors
for NMNAT1 promoter–luciferase vector (pLightSwitch_Prom: Product # S705857; Switch Gear
Genomics; Carlsbad, CA) and a Renilla vector from Promega (Madison, WI), according to Switch
Gear Genomics Light Switch Luciferase Assay Systems protocol. Promoter activity was
determined by utilizing Promega’s firefly dual luciferase promoter activity assay and a Qiagen
plate reader (Section 2.3.13). NMNAT1 promoter activity was assessed relative to the Renilla
vector control and then normalized to shNT1. The experiments were performed in high glucose
(4.5 g/l) media after overnight seeding with fresh media change as established and performed in
the previous experiments.
shBCA2-KD resulted in increased NMNAT1 promoter activity in both cell lines compared
to the non-targeted controls (MDA-MB-468: 409% and 459%; MDA-MB-231: 175% and 169%).
Interestingly, results for all these experiments were only statistically significant when the
experiments were performed under “high” glucose conditions, for time periods not greater than 24
hours after seedings, and a confluence below ~70%. If any of those factors were not controlled,
the results became inconsistent and uninterpretable.
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The dependence of the inverse correlation between BCA2 and NMNAT1 on glucose
concentration in the media, confluence, and seeding time suggests that the metabolic state of the
cells is essential to the observed findings. This suggests that the concentration of glucose in the
media must be sufficient for shBCA2-KD to induce NMNAT1 expression at the level of the
promoter. Therefore, high glucose may be a necessary intermediate metabolite in the mechanism
regulating NMNAT1 expression in response to genetic inhibition of BCA2.
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Figure 4.3 shBCA2-KD significantly increased NMNAT1 promoter activity determined by
dual renilla luciferase assay in both TNBC cell lines
shBCA2-KD resulted in an increase in NMNAT1 promoter activity. NMNAT1 promoter activity
is significantly increased in response to shBCA2-KD in both cell lines as determined by a firefly
renilla luciferase dual reporter assay, which normalizes promoter activity to β-actin relative to
shNT control. In MDA-MB-468 cell lines, promoter activity increased to 409% and 459% in
shBCA2-1 and shBCA2-2 KD clones, respectively. In MDA-MB-231 cells, promoter activity also
increased by 175% and 169% in shBCA2-1 and shBCA2-2 KD clones. This, combined with the
previous data, suggests that BCA2 is a regulating expression of NMNAT1 protein and transcripts
at the level of NMNAT1 transcription.
4.4

Discussion
BCA2 negatively regulates the expression of the NMNAT1 protein and transcripts, as well

as at the promoter activity level. The limitations of this study were that they do not delineate a
specific mechanism by which BCA2 is modulating NMNAT1 expression. Given that BCA2 is an
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E3-ligase, it is likely that BCA2 exhibits its activity through its ubiquitinating activity. In order to
further investigate the exact mechanism by which BCA2 is modulating NMNAT1 expression,
rescue experiments with wild type (WT) and mutant (MT) variants of BCA2 would help to define
the functional domain of BCA2 that the changes in NMNAT1 expression depend on.
If the rescue studies with BCA2-WT reversed the increase in NMNAT1 observed in the
previous findings, and one of the mutant variants of BCA2 did not rescue the observations, then
the specific region mutated in the BCA2-MT would be identified as a strong candidate for the
mechanism of action by which BCA2 regulates NMNAT1 expression. Specifically, if a BCA2-E3
-MT was unable to rescue original findings, this would suggest that the E3 domain of BCA2 is
responsible for regulating NMNAT1 directly or through some intermediate. In order to determine
potential binding partners of the theoretical BCA2-E3 ligase, a ubiquitin enrichment assay could
be used to identify protein ubiquitinated in the BCA2-WT and not ubiquitinated in the BCA2-E3MT. Any identified proteins in the ubiquitinated population of cells would be a good candidate for
an intermediate regulator of NMAT1 by BCA2.
Future studies should focus on elucidating the stability of BCA2 protein in response to
glucose deprivation, utilizing cycloheximide to determine how long the protein is stable. The role
of BCA2 in regulating whole cell metabolism (metabolomic profile of shNT vector shBCA2)
would also be valuable as it could identify potential points in the metabolic pathway, which could
be potential chemotherapeutic targets of BCA2. Potential targets could later be verified by
immunoprecipitation assays to pull down BCA2 associated proteins, as well as evaluating the
ubiquitinated proteins in the presence or absence of BCA2 by shBCA2-KD. Finally, the
mechanism by which BCA2 is regulating NMNAT1 expression needs to be further explored to
determine.
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CHAPTER 5: shBCA2-KD INHIBITS KEY MARKERS OF WARBURG METABOLISM
(LDHA/LDHB) AND DECREASED WARBURG-LIKE METABOLISM
AND PROLIFERATION
The positive correlation between glucose concentration and expression of BCA2 and the
inverse correlation of BCA2 and NMNAT1 is consistent with the hypothesis that BCA2 is a
regulator of glucose (Warburg-like) metabolism. In order to investigate this further, shBCA2
clonal populations were evaluated by western blot for key markers of Warburg-like metabolism
and the functional consequences on Warburg-like metabolism and cellular proliferation.
5.1

shBCA2-KD is associated with a decrease in Warburg-like metabolism as measured by
the observed ratio of LDHA/LDHB
In order to further investigate the finding that shBCA2-KD resulted in decreased Warburg-

like metabolism the expression of LDHA and LDHB protein levels were evaluated by western blot
analysis in MDA-MB-231 and MDA-MB-468 cells. The findings revealed that a decrease in
expression of the oncogene BCA2 was accompanied by a decrease in protein expression for
LDHA, and a corresponding increase in LDHB. This decreased ratio of LDHA/LDHB is a known
measure of Warburg-like metabolism (Burns & Manda, 2017). The knockdown of BCA2 again
was associated with a concurrent upregulation of NMNAT1 protein expression. This was
accompanied by a decrease in LDHA expression and an increase in LDHB protein expression
(Figure 5.1), which suggested an overall decrease in Warburg-like metabolism.
These research findings verify that BCA2 and NMNAT1 are inversely correlated in both
cell lines. The rest of the shBCA2-KD western blots not only recapitulated the previous findings
of the inverse correlation between BCA2/NMNAT1, but also validated the proposed hypothesis
that BCA2 modulates glycolysis and Warburg-like metabolism. In order to further investigate and
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shBCA2-KD is Associated with a Decrease in Key Markers of Warburg (LDHA/LDHB)

A.

shBCA2-KD is Associated with a Decreases in the Ratio of Key Enzymatic
Markers (LDHA/LDHB) of Warburg Metabolism
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Figure 5.1 shBCA2-KD is Associated with a Decrease in the Ratio of key Enzymatic Markers
of Warburg-like metabolismMetabolism (LDHA/LDHB).
shBCA2-KD decreased the ratio of LDHA/LDHB and upregulation of NMNAT1. Increased
NMNAT1 (MDA-MB-468: 515%, 599%, and 370%) and (MDA-MB-231: 655%, 626%, and
1294%). Decreased LDHA (MDA-468: 58%, 27%, and 14%) and (MDA-231: 26%, 22%, and
19%), and increased LDHB (MDA-468: 315%, 375%, and 370%) and (MDA-231: 335%, 324%,
and 397%). The data show that shBCA2 increases NMNAT1 and decreases LDHA/LDHB,
Warburg-like markers. Representative blots are displayed of experiments performed in triplicate,
and densitometry was analyzed with Image-J (see section 2.3.5).
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validate these findings, it was necessary to measure the consumption of glucose and the production
of lactate.
These findings suggest that BCA2 is playing a role in the regulation of the expression of
LDHA and LDHB, which are established markers of the relative Warburg-like metabolism in the
cell (Burns & Manda, 2017). The results also suggest that these phenomena are at least associated
with a change in NMNAT1 expression. However, the exact mechanism and functional
consequences are unclear. In order to determine the functional consequences of the effects of
shBCA2-KD on LDHA/LDHB, the extent of glucose consumption and lactate production were
used as measures of Warburg-like metabolism.
5.2

shBCA2-KD decreased glucose consumption and decreased lactate production
An analysis of the glucose and lactate concentrations was performed in triplicate on the

media of the disparate clonal cell lines in order to assess the relative Warburg-like activity of the
shBCA2-KD cell lines and the consequences of shBCA2-KD of BCA2 protein expression. This
was conducted over time and relative to the shNT control (Figure 5.2). Statistical analysis of the
difference in concentrations for shNT-controls (MDA-MB-468 and MDA-MB-231) relative to
shBCA2-KD 12 and 24 hours after treatment (at zero hours), revealed a decrease in glucose
consumption and lactate production.
Rate analysis of glucose consumption and lactate production using a two-tailed student ttest and three observations, or replicates for each sample, revealed that shBCA21-KD of BCA2 in
the TNBC cell lines (MDA-MB-468 and MDA-MB-231) resulted in a decrease in key markers of
Warburg-like metabolism. Knockdown of BCA2 expression resulted in an approximate 30%
(t(2)=1.63, p=0.24) and 24% (t(2)=1.29, p=0.32) decrease in glucose consumption in MDA-MB468 at 12 hours after treatment. Although reductions in glucose production were observed, the data
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was not statistically significant, most likely due to the large variance of the control sample.
However, in MDA-MB-231 cells, a significant reduction of 25% (t(4)=4.37, p=0.01) and 23%
(t(4)=2.88, p=0.04) was recorded 24 hours after treatment (Figure 5.2).
The production of lactate is a significant marker used to assess the extent of Warburg-like
activity in cancer cell lines. The key aspect of cellular metabolism, which is modulated when
normal cells undergo a metastatic transformation, is that there is an increase in glycolysis (Jang,
Kim, & Lee, 2013) followed by an increase in lactate production as the pathway shuts pyruvate
away from the TCA-Cycle and toward glycolysis.
The production of lactate is significantly increased in tumor cells. This change increases
the acidity of the microenvironment, resulting in increased metastasis and a significant change in
the behavior of the cells (Burns & Manda, 2017). In addition to increased acidity, increased lactate
“anaerobic” metabolism is associated with increased ATP (energy) production within the cancer
cells. However, despite a decrease in energy production efficiency per mole of glucose, cancer
cells produce ATP at a greater rate than normal cells. ATP and glycolysis are essential for rapid
cellular proliferation. ATP is needed for energy, while glycolysis produces excess biological
metabolites necessary for rapid proliferation (Burns & Manda, 2017).
In the shBCA2-KD cells, there was a significant decrease in lactate production in both cell
lines (Figure 5.2). At 12 hours after treatment, lactate production was decreased by 31% (t(4)=6.08,
p=0.003) and 28% (t(4)=6.18, p=0.003) relative to the shNT control in MDA-MB-468 cells. In
addition, lactate production was decreased by 47% (t(4)=34.38, p<0.001) and 55% (t(4)=34.28,
p<0.001) in MDA-MB-231 cells at 12 hours after treatment, and 32% (t(4)=5.77, p=0.004) and
36% (t(4)=11.73, p<0.001) at 24 hours after treatment. These data suggest that Warburg-like
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metabolism is linked to BCA2 protein expression and that this effect may be mediated through
NMNAT1 (See Figure 5.2).
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Figure 5.2 shBCA2-KD is Associated with a Decrease in Glucose Consumption and
Lactate Production.
The analysis of glucose and lactate concentrations was performed in triplicate on the media of the
disparate clonal cell lines. High glucose consumption and lactate production were associated with
Warburg-like metabolism. shBCA2-KD significantly (*) decreased lactate production in MDAMB-468 cells (12 hours) (31% (t(4)=6.08, p=0.003) and 28% (t(4)=6.18, p=0.003)) and both
glucose consumption (25% (t(4)=4.37, p=0.01) and 23% (t(4)=2.88, p=0.04)) and lactate
production (32% (t(4)=5.77, p=0.004) and 36% (t(4)=11.73, p<0.001)) in MDA-MB-231 cells (24
hours), as indicated by the asterisk in each graph. These data are consistent with a decrease in
Warburg-like metabolism, and the change in LDHA/LDHB ratio.
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5.3

shBCA2-KD results in significantly decreased rates of cellular proliferation
After evaluation of the effects of shBCA2-KD on protein expression, glucose consumption,

and lactate production after 12 and 24 hours, we evaluated the relative proliferation rates of both
MDA-MB-468 and MDA-MB-231 TNBC cell lines against the shNT-control group. In previous
studies, transient knockdown (siBCA2) resulted in a decrease in relative proliferation rates of
MDA-MB-468 and MDA-MB-231 TNBC cell lines (Buac et al., 2013).
In this study, proliferation rates were conducted in triplicate and analyzed using the
Beckman Coulter particle counter and corrected for the dilution factor and the total volume of the
cell suspension collected. The number of cells per well were calculated by subtracting the total
number of cells per well on day zero from the total number on day four. Proliferation rates were
then calculated relative to the control group. Three counts were collected for each sample on each
day.
shBCA2-KD significantly decreased proliferation in both cell lines. MDA-MB-468
decreased proliferation by 49% (t(4)=54.07, p<0.001) and 47% (t(4)=53.61, p<0.001) while in
MDA-MB-231 proliferation decreased by 28% (t(2)=8.29, p=0.001 and 28% t(2)=26.80, p<0.001)
relative to the shNT targeting control. These results are consistent with shBCA2-KD decreasing
tumor cell proliferation as previously reported.
5.4

Discussion
The inhibition of BCA2 results in an increase in NMNAT1 protein expression, as well as

a decrease in expression of LDHA and an increase in LDHB. The decrease in the ratio of
LDHA/LDHB protein expression is indicative of a decrease in Warburg-like metabolism and is
characterized by decreased glucose consumption and decreased lactate production. These results
indicate that BCA2 plays a significant role in the regulation of Warburg-like metabolism.
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shBCA2-KD Decreases Proliferation Rates
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Figure 5.3 shBCA2-KD Decreases Proliferation Rates Relative to Non-Targeting Controls
The relative proliferation rates of both MDA-MB-468 and MDA-MB-231 TNBC cell lines with
shBCA2-KD were compared against the shNT-control group and were conducted in triplicate.
shBCA2-KD significantly (*) decreased the relative proliferation rates of MDA-MB-468 (49%
(t(4)=54.07, p<0.001) and 47% (t(4)=53.61, p<0.001)) and MDA-MB-231 (28% (t(2)=8.29,
p=0.001 and t(2)=26.80, p<0.001) TNBC cell lines relative to the shNT targeting control
populations (indicated by the asterisks). The number of cells were directly counted by a Beckman
Coulter particle (Cell) counter and proliferation rates were run in triplicate.
The proceeding findings demonstrated a change in Warburg-like metabolism in response
to shBCA2-KD. However, they did not offer any insights into the mechanism by which BCA2 is
regulating Warburg-like metabolism. Future directions should evaluate protein and transcript data
for LDHA and LDHB in response to shBCA2-KD and BCA2-WT rescue to determine if the effects
of shBCA2-KD are specific to BCA2, and whether the change in LDHA and LDHB expression is
observed at the protein or transcript level.
Furthermore, the exact mechanism by which BCA2 regulates NMNAT1 expression could be
evaluated by the introduction of mutant constructs of BCA2 into the shBCA2-KD background to
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explore which, if any, mutant constructs are able to rescue the knockdown effects. If any specific
mutant variant failed to rescue or exclusively rescues expression of NMNAT1 in the shBCA2-KD
cells, this would be a strong indicator of the functional group on BCA2 that contributes to the
regulation of NMNAT1 expression.
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CHAPTER 6: shNMNAT1-KD INDUCED KEY MARKERS OF WARBURG-LIKE
METABOLISM (LDHA/LDHB), INCREASED WARBURG-LIKE
METABOLIC ACTIVITY AND PROLIFERATION
6.1

shNMNAT1-KD increases expression of BCA2, LDHA/LDHB, Warburg-like
metabolic activity and tumor cell proliferation
Knockdown of NMNAT1 by shNMNAT1 significantly decreased the expression of

NMNAT1 protein. As predicted in Figure 1.9, knockdown of NMNAT1 was associated with an
increase in BCA2 protein expression, suggesting an inverse relationship between BCA2 and
NMNAT1 protein expression. However, the relationship between BCA2 and NMNAT1 and their
potential roles in the regulation of Warburg-like metabolism may be either dependent or
independent of each other’s expression.
shNMNAT1-KD resulted in an increase in relative BCA2 protein expression (MDA-MB468: 7070%, 6286%, and 8427%; MDA-MB-231: 425%, 583%, and 418%) relative to the control.
To examine the effects of NMNAT1 on LDHA and LDHB, their relative levels were identified on
western blot and quantified by densitometry. shNMNAT1-KD also increased LDHA expression
(MDA-MB-468: 256%, 289%, and 346%; MDA-MB-231: 425%, 583%, and 418%) and was
associated with a decrease in LDHB (MDA-MB-468: 18%, 21%, and 9%; MDA-MB-231: 11%,
17%, and 35%). Altogether, shNMNAT1-KD was associated with upregulation of BCA2 protein
expression and an increase in the observed ratio of LDHA/LDHB, suggesting that Warburg-like
activity may also be enhanced (Figure 6.1).
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shNMNAT1-KD Results in Increased BCA2 Protein Expression,
and in the Ratio of Markers Warburg-like Metabolism (LDHA/LDHB)
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Figure 6.1 shNMNAT1 KD results in an increase of BCA2 expression, and an enhancement
of Warburg-like metabolic markers (LDHA/LDHB).
Stable knockdown of NMNAT1 by shNMNAT1 resulted in a significant increase in expression of
BCA2 protein, as determined by western blotting. In addition, there was a significant increase in
LDHA expression and a concurrent decrease in LDHB protein expression. This increase in the
ratio of LDHA/LDHB is indicative of Warburg-like metabolism. LDHA is the more active homoisoform of LDH, which is a key enzyme in lactate metabolism and, therefore, likely drives cells
towards increased lactate production.
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6.2

shNMNAT1-KD of NMNAT1 increased glucose consumption and lactate production
An evaluation of the glucose and lactate concentrations in the media was performed in

triplicate of the multiple clonal cell lines in order to assess relative Warburg-like activity of the
shNMNAT1-KD cell lines and the consequences of shNMNAT1-KD on glucose consumption and
lactate production. These experiments were conducted at 12 hours and were normalized relative
to the shNT control and the number of cells per plate. Cells were seeded the night before. The
media was changed with high glucose media at time zero when the first sample was collected.
Subsequent samples were collected for high glucose media at 12 hours. The glucose and lactate
levels in the media were analyzed by Dr. Wang’s lab using their protocol described in the methods
sections. Statistical analysis of the differences in concentrations for the shNT-controls (MDA-MB468 and MDA-MB-231) relative to shBCA2-KD, revealed an increase in glucose consumption
and lactate production (for a detailed explanation of the experimental procedure associated with
glucose consumption and lactate, as well as the scientific rigor and statistical analysis used to
evaluate the data please see the following sections: 2.1, 2.2, 2.3.6, and 2.3.10-13).
Glucose consumption and lactate production (using a two-tailed student t-test and three
replicates for each sample) revealed that shNMNAT1-KD in TNBC cell lines (MDA-MB-468 and
MDA-MB-231) resulted in an increase in key markers of Warburg-like metabolism. Evaluation of
the effects of NMNAT1-KD after 12 hours on Warburg-like metabolism revealed that NMNAT1KD was associated with a significant increase in glucose consumption (Figure 6.2) in MDA-MB468 cells, with samples yielding 349% (t(4)=-13.87, p<0.001) and 400% (t(4)=-9.00, p<0.001)) of
the glucose consumption compared to the non-targeting control at time zero. NMNAT1-KD in
MDA-MB-231 cells also resulted in an increase in glucose consumption, 139% (t(4)=3.74, p=0.02)
and 154% increase (t(4)=-1.13, p=0.32) (Figure 6.2).
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Figure 6.2 shNMNAT1 KD Increased Glucose Consumption and Lactate Production
At 12 hours after treatment, knockdown of NMNAT1 by shNMNAT1 results in a change in
glucose consumption with a significant (*) increase in glucose consumption in MDA-MB-468
(349% (t(4)=-13.87, p<0.001) and 400% (t(4)=-9.00, p<0.001)), and in MDA-MB-231 (39%
Increase (t(4)=3.74, p=0.02) and a 54% increase (t(4)=-1.13, p=0.32). In addition, shNMNAT1
revealed a significant increase in lactate production in both cell lines: MDA-MB-468 (4,955%
[t(2)=-4.01, p=0.05] and 6,337% [t(4)=-21.13, p<0.001]) and MDA-MB-231 (634% [t(2)=-23.44,
p=0.001] and 1,265% [t(2)=-32.88, p<0.001]). These experiments were performed in triplicate and
are suggestive that decreased NMNAT1 plays a significant role in conversion to aerobic
metabolism through changes in glucose consumption and a shift towards increased lactate
production. These results are consistent with increased Warburg-like effect.
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Increased lactate production is consistent with Warburg-like metabolism. Increased lactate
production is generally associated with a concurrent increase in glucose consumption as a result
of the decreased efficiency of Warburg-like metabolism in ATP production (Burns & Manda,
2017). This factor is a key component to functional MRI studies (Wang et al., 2016). These
machines utilize radioactive isotypes of glucose to determine glucose uptake in tissues, thus
indicating the potential for tumor formation (Burns & Manda, 2017; Wang et al., 2016). As
opposed to a normal cell’s aerobic metabolism, cancer cells exhibit anaerobic metabolism, which
requires an increase in glucose consumption (Burns & Manda, 2017; Krisher & Prather, 2012;
San-Millan & Brooks, 2017; Vander Heiden et al., 2009; Zdralevic et al., 2018).
The results revealed that shNMNAT1-KD resulted in a dramatic and statistically
significant increase in lactate production in both MDA-MB-468 (4,955% [t(2)=-4.01, p=0.05] and
6,337% [t(4)=-21.13, p<0.001]) and MDA-MB-231 (634% [t(2)=-23.44, p=0.001] and 1,265%
[t(2)=-32.88, p<0.001]).
These results indicate shNMNAT1-KD increases glucose consumption and lactate
production. The results also suggest that it is possible that decreased NMNAT1 expression alters
both the mechanism and flux of glucose utilization in both cell lines. shNMNAT1 enhances
glucose metabolism and shunts the glucose metabolic pathway towards the anaerobic lactic acid
cycle (TCA-Cycle). However, the distinct increase of lactate production is a more prevalent and
relevant indicator for anaerobic glycolysis. Therefore, the minimal effects of shNMNAT1 on
increased glucose consumption is not as significant as the robust increase in lactate production in
both cell lines. These findings are consistent with an enhancement of Warburg-like metabolism.
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6.3

shNMNAT1-KD results in a significant increase in cellular proliferation
The relative proliferation rates of MDA-MB-468 and MDA-MB-231 increased in response

to shNMNAT1-KD. In this study, proliferation assays (in triplicate) were measured using the
Beckman Coulter particle counter according to the manufacturer’s instructions and normalized to
the nontargeting control (section 2.3.6). The increase in the number of cells per well was calculated
by subtracting the total number of cells per well on day zero from the total number on day four.
Proliferation rates were then calculated relative to the control group. Three counts were collected
for each sample on each day. The proliferation of cells increased significantly in both cell lines.
shNMNAT1-KD significantly (*) increased the proliferation rates of MDA-MB-468 (228.4%
p<0.001 and 278.0% p<0.001) and MDA-MB-231 (283.6% p=0.001 and 285.5% p<0.001) TNBC
cell lines relative to the shNT targeting control populations (as indicated by the asterisk in Figure
6.3).
The combined results of the shNMNAT1 data showed that the effects of shBCA2-KD are
reversed when NMNAT1 is knocked down. shNMNAT1-KD increased: (a) the expression of
BCA2, which is a known oncogene, (b) the ratio of LDHA/LDHB (markers of Warburg-like
metabolism), (c) glucose consumption, and (d) lactate production. All these findings, together with
the data for shBCA2 suggest that BCA2 may have a role in driving Warburg-like metabolism
through the activity of NMNAT1. Conversely, increased NMNAT1 expression is associated with
decreases in BCA2 expression as well as a concurrent decrease in Warburg-like metabolism and
cellular proliferation rates. Induction of NMNAT1 by shBCA2-KD may occur by removing
suppression of the NMNAT1 promoter by BCA2. Promoter suppression of NMNAT1 could be
occurring either directly, or indirectly through BCA2’s activity.
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Figure 6.3 shNMNAT1-KD Increased Proliferation Rates Relative to Non-Targeting
Controls.
The relative proliferation rates of both MDA-MB-468 and MDA-MB-231 TNBC cell lines with
shNMNAT1-KD were compared against the shNT-control group and were conducted in triplicate.
shNMNAT1-KD significantly (*) increased the relative proliferation rates of MDA-MB-468
(228.4% p<0.001) and (278.0% p<0.001) and MDA-MB-231 (283.6% p=0.001 and 285.5%
p<0.001) TNBC cell lines relative to the shNT targeting control populations (as indicated by the
asterisk). The number of cells were directly counted by a Beckman Coulter particle (Cell) counter.

These findings suggest that inhibition of NMNAT1 plays a role in the activation of
Warburg-like metabolism and is associated with increased BCA2 expression. Therefore,
NMNAT1 protein expression inhibits Warburg-like metabolism. However, the precise mechanism
by which NMNAT1 regulates Warburg-like metabolism requires further exploration.
6.4

Discussion
In order to further investigate the potential roles of BCA2 and NMNAT1 in the regulation

of cellular energy homeostasis, RNAi technology was utilized to inhibit BCA2, NMNAT1, and
BCA2/NMNAT1 (Chapter 7) protein expression in the TNBC cell lines MDA-MB-231 and MDAMB-468. The initial studies with shBCA2-KD demonstrated that loss of BCA2 resulted in: (a)
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increased expression of the tumor suppressor NMNAT1, (b) decreased expression of LDHA, (c)
increased LDHB, and (d) decreased functional markers of Warburg-like metabolism including
decreased glucose consumption, lactate production, and cellular proliferation. These results
suggest that BCA2 plays a critical role in the activation of Warburg-like metabolism and that loss
of BCA2 (associated with increased NMNAT1 expression) is sufficient to decrease the Warburglike metabolism in TNBC cells. In addition, measurements of key Warburg-like metabolism
markers (LDHA/LDHB) revealed that shBCA2-KD not only resulted in an increase of NMANT1
protein expression, but an increase in the ratio of LDHA/LDHB, an established marker of
Warburg-like metabolism (Lu et al., 2015; Rani & Kumar, 2019).
Warburg-like metabolism is characterized by an increase in glucose consumption, lactate
production, and relative proliferation rates (Brand, 2010; Burns & Manda, 2017; Zdralevic et al.,
2018). In order to determine the role of NMNAT1 in BCA2 dependent modulation of Warburglike metabolism stable shNMNAT1-KD clonal populations were generated as described
previously (Molina et al., 2014), and key markers of Warburg-like metabolism (LDHA and
LDHB) were assessed by western blot. In addition, functional assays for glucose consumption,
lactate production and cellular proliferation rates were performed to assess the consequences of
shNMNAT1-KD on the relative Warburg-like activity of the resulting shNMNMAT1-KD in
TNBC cells.
shNMNAT1-KD resulted in increased expression of BCA2 protein as determined by
western blot analysis. shNMNAT1-KD increased expression of LDHA a key marker of enhanced
Warburg-like metabolism, and decreased expression of LDHB, a marker known to be associated
with diminished Warburg-like metabolism. In addition, shNMNAT1-KD modulated functional
markers of Warburg-like metabolism resulting in increased glucose consumption, increased lactate
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production, and increased cellular proliferation. These results suggest that NMNAT1 suppresses
Warburg-like metabolism through some unknown mechanism and that inhibition of NMNAT1 is
sufficient to increase Warburg-like metabolism in the presence of BCA2 in TNBC cells MDAMB-468 and MDA-MB-231. The combined data from the shBCA2-KD and the shNMNAT1-KD
experiments suggests that BCA2 and NMNAT1 play dynamic and pivotal roles in the regulation
of Warburg-like metabolism. Hence, an exploration of the effects of a double knockdown was
warranted.
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CHAPTER 7: shBCA2/NMNAT1-KD RESCUED THE EFFECTS OF SHBCA2-KD ON
KEY MARKERS FOR WARBURG-LIKE METABOLISM (LDHA/LDHB)
AND PROLIFERATION
In order to further assess the association between BCA2 and NMNAT1, pGIPZ shRNA
plasmids specific to NMNAT1 (shNMNAT1) were serially transfected into the existing model
systems in both cell lines as shown here: (shNT2 = shNT1plko + shNTpGIPZ), (shNMNAT1-1-3
=shNT1

+

shNMNAT1-(1-3)

and

shBCA2/NMNAT1

=shBCA2+shNMNAT1-(1-3)).

Transfection was performed according to Mirus T1 transfection protocol every 48 hours for three
successive transfections with antibiotic selection media applied between transfections. After the
final transfection, the cells were selected in media containing high dose antibiotics for two weeks,
which was determined empirically by a kill curve. Cells were then allowed to recover in an
antibiotic-free media before being passaged into 96 well plates to perform a serial dilution of the
stable populations of cells to provide clonal populations for each plasmid. Clonal populations were
expanded, preserved, and then characterized by western blot, media analysis (glucose and lactate),
and proliferation rates.
Once the stable shBCA2/NMNAT1-dKD cell lines (shBCA2/NMNAT1-dKD) were
generated and stabilized, they were characterized by western blot to assess BCA2, NMNAT1, and
LDHA/LDHB, the key enzymes involved in the transition to Warburg-like metabolism.
Experiments were performed in triplicate on three different occasions, and parallel experiments
were carried out to evaluate protein expression levels through western blot and metabolic function
(glucose consumption and lactate production) at the same time. These experiments were performed
in parallel in order to ensure that the western blot and transcript data coincided with the media
analysis data.
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Densitometry was performed on all images, and error bars are shown. Representative
western blots are shown that were representative of the densitometry data. These included analysis
of LDHA, LDHB, BCA2, and NMNAT1 in the model system: shNT1, shBCA2, shNMNAT1,
shNT2, and shBCA2/NMNAT1-dKD cells (Figure 7.1).
7.1

shBCA2/NMNAT1-dKD resulted in a reversal or rescue of the effects of shBCA2-KD
on markers of Warburg-like metabolism by western blot
These results confirmed that BCA2 was still significantly reduced in the shBCA2-KD cells

and confirmed the decreased protein expression of BCA2 (MDA-MB-468: 33% and 32%, MDAMB-231: 7% and 5%), increased NMNAT1 (MDA-MB-468: 187% and 173%, MDA-MB-231:
212% and 202%), decreased LDHA (MDA-MB-468: 187% and 173%, MDA-MB-231: 212% and
202%), increased LDHB (MDA-MB-468: 573% and 480%, MDA-MB-231: 703% and 583%),
and recapitulated the role of BCA2 in inhibition of NMNAT1, and enhancing Warburg-Like
metabolism. This was consistent with previous studies in the literature that have demonstrated the
correlation between the ratio of LDHA/LDHB and Warburg-like metabolism (Molina, et al.,
2014).
Double knockdown of BCA2 and NMNAT1 (shBCA2/NMNAT1-dKD), relative to the
shNT2 control background, resulted in an increase in expression of LDHA, and decreased the
expression of LDHB. Relative to the shNT control, shBCA2/NMNAT1-KD decreased protein
expression of BCA2 (MDA-MB-468: 20% and 20%, MDA-MB-231: 5% and 1%), decreased
NMNAT1 (MDA-MB-468: 36% and 41%, MDA-MB-231: 14% and 23%), increased LDHA
(MDA-MB-468: 221% and 246%, MDA-MB-231: 83% and 196%), increased LDHB (MDA-MB468: 573% and 480%, MDA-MB-231: 703% and 583%), and recapitulated the role of BCA2 in
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shBCA2/NMNAT1-dKd Results in Reversal of the Effects of shBCA2-KD
on Key Markers of Warburg-Like Metabolism (Increased: LDHA/LDHB)
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Figure 7.1 shBCA2/NMNAT1-dKD Resulted in Reversal of the Effects of shBCA2-KD on
Key Markers of Warburg-Like Metabolism (Increased: LDHA/LDHB).
Western blot analysis, with densitometry, revealed significant changes in the ratio of
LDHA/LDHB in response to both shBCA2-KD and shBCA2/NMNAT1-dKD. Both control
vectors showed no significant changes. shBCA2-KD resulted in decreased BCA2 (MDA-MB-468:
33% and 33%, and MDA-MB-231: 7% and 5%), increased NMNAT1 (MDA-MB-468: 187% and
173%, and MDA-MB-231: 212% and 202%), decreased LDHA (MDA-MB-468: 40% and 41%,
and MDA-MB-231: 24% and 6%) and increased LDHB (MDA-MB-468: 573% and 480%, and
MDA-MB-231: 703% and 583%)}. Double knockdown rescued the shNT control’s expression of
LDHA and LDHB. shBCA2/NMNAT1-dKD resulted in a decrease in BCA2 protein expression
(MDA-MB-468: 20% and 20%, and MDA-MB-231: 5% and 1%), Decreased NMNAT1 protein
expression (MDA-MB-468: 36% and 41%, and MDA-MB-231: 14% and 23%), Increased LDHA
protein expression (MDA-MB-468: 221% and 246%, and MDA-MB-231: 21% and 49%) and
increased LDHB protein expression (MDA-MB-468: 321% and 280%, and MDA-MB-231: 83%
and 196%) relative to the shNT control vectors. Densitometry data is representative of three
separate experiments (standard errors are shown).
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inhibition of NMNAT1 and enhancing Warburg-Like metabolism. This constitutes a reversal or
rescue of the effects of shBCA2-KD on the TNBC cells.

7.2

shBCA2/NMNAT1-dKD resulted in a reversal or rescue of the decreased glucose
consumption and the production of lactate relative to shNT.
After characterizing the shBCA2/NMNAT1-dKD cells by western blot, an analysis of the

consumption of glucose and the production of lactate was conducted in these cells in triplicate
(Figure 7.2). These results suggest that BCA2 may play a significant role in glucose consumption.
At 24 hours after treatment, shBCA2 significantly decreased glucose consumption by 64%
(t(4)=7.98, p=0.001) and 72% (t(4)=12.15, p<0.001) in MDA-MB-468 cells. However, in MDAMB-231 cells, mixed results were observed. Namely, one sample generated a significant decrease
of 41% (t(4)=4.87, p=0.01) while the other showed no significant change in glucose consumption
(84%, t(2)=0.005, p=0.99). shBCA2/NMNAT1-dKD did not significantly alter glucose
consumption, as compared to the control in the MDA-MB-468 cell line, with relative rates of 100%
(t(4)=-0.05, p=0.96) and 177% (t(2)=-2.25, p=0.15), but did demonstrate a significant reduction
of 62% (t(4)=9.22, p<0.001) and 67% (t(2)=13.43, p=0.005) in the MDA-MB-231 cell line. The
negative control demonstrated a significant increase in glucose consumption, as compared to the
control (196%, t(4)=-6.87, p=0.002) in MDA-MB-231 cells. However, no significant difference
was observed between controls in MDA-MB-468 cells (t(2)=1.51, p=0.27).
These results demonstrated that shBCA2/NMNAT1-dKD rescued the glucose
consumption in the MDA-MB-468 cell line, suggestive of a renewal of Warburg metabolism. This
reversal was not observed in the MDA-MB-231 cell line. However, it is unclear whether these
results are replicable since the negative control also produced a significantly different rate of
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glucose consumption as compared to the control. A possible explanation for this could be attributed
to issues during the transduction process resulting in the selection of a subsequent cellular
population not originally targeted. The random insertion of genetic material during transduction
can disrupt other off-target genes, which could result in this phenomenon. Furthermore,
shBCA2/NMNAT1-dKD played a significant role in lactate metabolism in the absence of BCA2
expression. shBCA2 decreased the production of lactate by 35% (t(4)=2.71, p=0.05) and 19%
(t(4)=1.29, p=0.27) in MDA-MB-468 at 24 hours after treatment, although these reductions were
not statistically significant. Larger and statistically significant reductions were observed in MDAMB-231, where shBCA2 resulted in a 56% (t(4)=7.04, p=0.002) and 64% (t(4)=13.31, p<0.001)
decrease in lactate production respectfully.
shBCA2/NMNAT1-KD resulted in a significant increase in lactate production, rescuing
the effects of shBCA2-KD on decreased lactate production, and elevating the production of lactate
above the shNT control levels. Lactate production increased 499% (t(4)=-26.71, p<0.001) and
496% (t(4)=-12.53, p<0.001) in MDA-MB-468, and 83% (t(4)=-12.25, p<0.001) and 81% (t(2)=4.40, p=0.04) in MDA-MB-231. The negative control also demonstrated a significant increase in
lactate production over the control in the MDA-MB-468 cell line (163%, t(4)=-5.56, p=0.03).
However, no significant difference was observed in the MDA-MB-231 cell line (t(4)=-2.54,
p=0.06). These findings again reiterate the importance of NMNAT1 expression in the modulation
of lactate metabolism as the production of lactate is the best indicator of anaerobic metabolism and
the dramatic effects that the modulation of NMNAT1 protein expression has on Warburg-like
metabolism. However, because of the increase seen in the negative control of the MDA-MB-468
cell line, it cannot be stated with certainty how much of the recovery in lactate production can be
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shBCA2/NMNAT1-KD Increased Glucose Consumption and Lactate Production
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Figure 7.2 shBCA2/NMNAT1-dKD rescued glucose consumption and Lactate production
relative to shBCA2-KD and shNT controls
NMNAT1 plays a significant role in both glucose consumption and metabolism, and a significant
(*) role in lactate metabolism. shBCA2/NMNAT1-dKD rescued glucose consumption relative to
shBCA2-KD conditions in the MDA-MB-468 cell line (100% (t(4)=-0.05, p=0.96) and 177%
(t(2)=-2.25, p=0.15)) but had a mixed effect in the MDA-MB-231 cell line (41% (t(4)=4.87,
p=0.01) and (84%, t(2)=0.005, p=0.99)). shBCA2/NMNAT1-dKD resulted in a significant
recovery of lactate production relative to both shBCA2-KD populations in the MDA-MB-231 cell
line (83% (t(4)=-12.25, p<0.001) and 81% (t(2)=-4.40, p=0.04)). The analysis was done in
triplicate.
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attributed to shBCA2/NMNAT1-KD, particularly when considering the initial decrease after
introducing shBCA2-KD was not significant.
7.3

shBCA2/NMNAT1-KD increased proliferation rates relative to non-targeting controls,
and rescued the decrease in proliferation associated with shBCA2
The effects of shBCA2/NMNAT1-KD on LDHA/LDHB protein expression, rescuing both

glucose consumption and lactate production, are all consistent with increased Warburg-like
metabolism both in MDA-MB-468 and MDA-MB-231 TNBC cell lines. To evaluate the functional
consequences of the dKD, relative proliferation rates were examined in triplicate and analyzed
using the Beckman Coulter particle counter according to the manufacturer’s instructions and
normalized to the non-targeting control. The increased number of cells per well were calculated
by subtracting the total number of cells per well on day zero from the total number on day four.
Proliferation rates were then calculated relative to the control group. Three counts were collected
for each sample on each day.
The proliferation of cells decreased significantly (*) in both cell lines in response to
shBCA2-KD MDA-MB-468 (33% p<0.001 and 19% p<0.001) and MDA-MB-231 (52% p=0.001
and 22% p<0.001) cells. When NMNAT1 was knocked down in the shBA2 cells, generating the
dKD clones (shBCA2/NMNAT1-KD), this significantly (*) increased the relative proliferation
rates of MDA-MB-468 (190% p<0.001 and 206% p<0.001) and MDA-MB-231 (228% p=0.001
and 278% p<0.001) relative to the shNT targeting control populations (as indicated by the asterisk
in Figure 7.3) .
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shBCA2/NMNAT1-Kd Increased Proliferation Relative to Control
and Rescued the Decreased Proliferation Associated with shBCA2-Kd
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Figure 7.3 shBCA2/NMNAT1-KD Increased Proliferation Rates Relative to Non-Targeting
Controls
The relative proliferation rates of both MDA-MB-468 and MDA-MB-231 TNBC cell lines
increased in response to dKD relative to the non-targeting controls and rescued the decrease in
proliferation associated with shBCA2-KD. Results for KD cells were compared against the shNTcontrol group and were conducted in triplicate. shBCA2/NMNAT1-KD significantly (*) increased
the relative proliferation rates of MDA-MB-468 (190% p=0.001 and 206% p<0.001) MDA-MB231 (228.4% p<0.001 and 278.0% p<0.001) TNBC cell lines relative to the shNT targeted control
populations as indicated by the asterisks. shBCA2 decreased proliferation of MDA-MB-468 (33%
p=0.001 and 19% p<0.001), MDA-MB-231 (52% p<0.001 and 22.0% p<0.001). The increase in
proliferation in response to the dKD resulted in a rescue and even enhancement of proliferation
greater than the control alone. The number of cells were directly counted by a Beckman Coulter
particle (Cell) counter.
7.4

Discussion
These data suggest that both BCA2 and NMANT1 have reciprocal roles in the regulation

of Warburg-like metabolism. However, the data is not clear as to whether this change in energy
metabolism is dependent on NMNAT1 or independent. To determine if the change in Warburg-
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like metabolism was associated with shBCA2-KD, a dKD was used to determine if the BCA2dependent changes were dependent on NMNAT1.
shBCA2/NMNAT1-dKD rescued the effects associated with shBCA2-KD on markers of
Warburg-like metabolism, including increased LDHA expression, decreased expression of LDHB,
and increased functional markers of Warburg-like metabolism (increased glucose consumption
and lactate production), as well as increased cellular proliferation. These results suggest that
inhibition of NMNAT1 plays a necessary role in the changes in Warburg-like metabolism
associated with shBCA2-KD of BCA2 protein expression. Hence, these data suggest that BCA2
and NMANT1 are playing reciprocal roles in regulation of Warburg-like metabolism in TNBC
cell lines. However, the data does not provide a specific mechanism by which NMNAT1 is
regulating the extent of Warburg-Like metabolism in response to modulation of BCA2 in these
cells.
The significant implications of these results are the importance of glucose concentration in
regulating multiple markers of cancer cell tumorigenicity (oncogenes and tumor suppressors).
These investigations dealt specifically with the role of BCA2 in the regulation of cellular glucose
metabolism. However, it was interesting to see that glucose concentrations had such significant
and rapid effects on the expression of both BCA2 and NMANT1 expression. It would be difficult
to determine the exact mechanism by which the BCA2: NMNAT1 axis is regulating glucose
metabolism in cancer cells and in response to glucose stimulation because of the diverse effects of
glucose on the metabolic state of the cells.
In order to identify the potential mechanisms by which BCA2 and NMNAT1 are regulating
Warburg-like metabolism, a few exploratory pilot experiments could be performed including
RNA-Seq, ubiquitin enrichment proteomics, or immunoprecipitation, and metabolomics analysis
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could be used to identify candidate intermediate proteins or metabolites. These “Omic” studies can
provide valuable lists of candidate proteins or metabolites that are modulated in response to genetic
manipulation of BCA2 and NMANT1 (shBCA2, shNMNAT1, shBCA2/NMNAT1). Once
candidate molecules are identified, traditional molecular chemistry techniques could be used to
validate the findings experimentally.
Studies utilizing glucose transporter inhibitors or L-Glucose could also be utilized to
determine if the changes in BCA2 and NMNAT1 are dependent on the influx of glucose into the
cell, or if some intermediate metabolite of glucose metabolism is involved in the regulation of the
system. This information would indicate whether the effects of glucose on BCA2, NMANT1,
LDHA, and LDHB expression are dependent on the state of glucose metabolism in the cell. If a
specific metabolite could be identified, public data on the metabolic sensors detecting that
metabolite, or the enzyme responsible for its conversion could provide valuable insights into the
potential mechanism by which glucose is regulating BCA2 and NMNAT1 expression.
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CHAPTER 8: CONCLUSIONS, LIMITATIONS, AND CLINICAL SIGNIFICANCE
The goal of this dissertation work was to expand on the role of BCA2 in the regulation of
cellular energy homeostasis, established previously in the Dou Lab by Dr. Buac-Ventro. The
preliminary work demonstrated that BCA2 modulates AMPK through some indirect mechanism.
Based on mechanistic studies with mutant BCA2 constructs and a pharmacological investigation
of the model system, an AKT dependent mechanism was suggested to be the cause. To identify a
potential mechanism or intermediary by which BCA2 was regulating AMPK activation and
cellular energy homeostasis, Dr. Buac-Ventro performed an siRNA-KD of BCA2 in MDA-MB231 cells with a phospho-peptide enrichment. The preliminary investigation did not identify any
potential AMPK interacting phosphoproteins. However, upon further investigation and evaluation
of the data by Dr. Wang and Dou, pNMNAT1 was identified as enriched in response to BCA2KD. This association was the basis for the rest of the investigations.
Due to the lack of a targetable receptor in TNBCs, patients suffer poor outcomes, and the
available chemotherapeutics have many off-target effects as a result of being cytotoxic drugs
(Park, Ahn, & Kim, 2018; Wahba & El-Hadaad, 2015). BCA2 has been identified as a risk factor
for invasive TNBCs (Brahemi et al., 2010; Burger et al., 2010). The association between BCA2
and TNBCs suggests that BCA2 may be a potential therapeutic target in the treatment of BCA2
positive TNBCs (Brahemi et al., 2010; Buac et al., 2013; Burger et al., 2010).
BCA2 was previously found to inhibit the activation of AMPK and is believed to do so
through an AKT dependent, albeit indirect mechanism (Buac et al., 2013). The extent of AMPK
activation is known to be correlated with glucose concentration in previous studies (Arkwright et
al., 2014; Salt, Johnson, Ashcroft, & Hardie, 1998). The preliminary findings from the Dou lab
performed by Dr. Buac-Ventro defined the association between BCA2 and AMPK with the
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regulation of cellular energy homeostasis. The literature described the role of glucose in the
regulation of AMPK signaling in response to cellular energy homeostasis, and the current
investigation sought to determine the role of BCA2 in glucose metabolism.
The initial phase of the investigation was intended to establish the experimental conditions
and baseline cellular metabolic activity in the context of different concentrations of glucose. This
was performed because glucose was known to regulate AMPK activation, so ideal glucose
conditions needed to be established to investigate the role of BCA2 on cellular energy homeostasis
successfully. The preliminary findings revealed a clear positive correlation between glucose
concentration and BCA2 protein expression, which was associated with a concurrent and inverse
decrease in NMNAT1 protein expression. The reverse was also found to be true, and these findings
represented a potential novel molecular mechanism for the regulation of BCA2 and NMNAT1 in
response to glucose levels in the cells. A critical aspect of cancer cell energy homeostasis is the
transformation of the cells’ primary source of energy from aerobic to anaerobic or “Warburg”
metabolism (Liberti & Locasale, 2016; San-Millan & Brooks, 2017; Vander Heiden et al., 2009;
Zdralevic et al., 2018).
The culmination of these findings, as illustrated in Figure 8.1, strongly suggests a potent
role for both BCA2 and NMANT1 in the regulation of Warburg-like metabolism in response to
glucose concentration. Glucose concentration is positively associated with Warburg metabolism
(Burns & Manda, 2017), and the combined findings strongly suggest a dynamic role for both
BCA2 and NMNAT1 in the regulation of Warburg-like metabolism. It was important to determine
what the functional consequences of these changes in BCA2 and NMANT1 expression were on
cellular energy metabolism and tumor cell proliferation.
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shBCA2-KD resulted in increased NMNAT1 protein, transcript, and promoter activity,
which is consistent with BCA2 regulating expression of NMNAT1 at the level of the promoter.
However, previous studies have shown that BCA2 is a cytoplasmic protein and NMNAT1 is a
nuclear protein, so it is likely there is some intermediary effector molecule modulating this
mechanism.
The significance of these findings is that BCA2 may present a potent and selective target for
the treatment of TNBCs. Because BCA2 is primarily expressed in early development and in
metastatic breast cancer cells, it is possible that it could be selectively targeted therapeutically.
Because Warburg metabolism is a fundamental and basic survival mechanism of all cancers,
targeting Warburg metabolism has therapeutic potential in that it would selectively inhibit tumor
cells over normal tissues. By studying Warburg metabolism and the mechanisms that facilitate its
transformation, researchers may reveal strategies and targets for the disruption or inhibition of
Warburg metabolism, specifically in cancer cells. These research findings potentially represent a
significant advancement in the targeted treatment of cancer.

8.1

Limitations
The limitations of this study include an incomplete evaluation of the extent of Warburg

metabolism in the respective experimental conditions. A seahorse analysis of the experimental
conditions (shNT, shBCA2, shNMNAT1 and shBCA2/NMNAT1) would have provided a more
complete picture of the functional consequences of the genetic manipulation of BCA2 and
NMNAT1 alone and in combination. Furthermore, a rescue experiment with BCA2-WT would
have demonstrated conclusively that the rescue phenomena observed in response to shNMNAT1KD was the direct result of BCA2 expression.
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Working Model: The Inverse Relationship Between BCA2 and NMNAT1
is an important Modulator of Warburg-Like Metabolism in TNBCCLs

Legend:
Inhibition (-)
Upregulation (+)

Figure 8.1 Potential Working Model for the Effects of BCA2 and NMNAT1 in regulation
of Warburg-like Metabolism.
In summary, BCA2 and NMNAT1 are inversely correlated in response to both glucose
concentration (inducible: in excess/deprivation) and genetic modifications by shRNAs. Increased
glucose concentration results in an increase in BCA2 protein expression and a decrease in
NMNAT1 expression. Findings suggest that BCA2 may inhibit NMNAT1 expression at the
protein level. This suggests that there may be an alternative mechanism by which BCA2 and
NMNAT1 regulate each other’s expression. NMNAT1 is the rate-limiting enzyme in NAD
synthesis, and NAD is the key coenzyme in the regulation of oxidation/reduction reactions.
NMNAT1 specifically localizes to the nucleus, thus modulating the pool of NAD in the nucleus.
NAD modulates DNA’s chromatin structure in the nucleus, thereby regulating transcriptional
activity through access to DNA by transcription factors. shBCA2-KD is also associated with a
decrease in Warburg-like metabolism. This is marked by a decreased ratio of LDHA/LDHB,
decreased glucose consumption, and increased lactate production. Conversely, shNMNAT1-KD
increases BCA2 protein expression, increases markers of Warburg-like metabolism (increase ratio
of LDHA/LDHB), and significantly increases lactate production and significantly affects glucose
consumption. shBCA2/NMNAT1-dKD increases the ratio of LDHA/LDHB, and significantly
increases the production of lactate, rescuing the decrease in glucose consumption and lactate
production resultant from shBCA2-KD. shBCA2/NMNAT1-dKD had no significant effect on
glucose consumption. These findings suggest that NMNAT1 plays a significant role in the
regulation of lactate metabolism and glucose consumption. These data are suggestive of inhibition
of anaerobic metabolism (normal cells) by BCA2, while NMNAT1 appears to inhibit Warburg
metabolism and significantly regulates lactate production.
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Additional experimentation with site MT (mutant) variants of BCA2 could reveal the
functional domain necessary for the role of BCA2 in the regulation of NMNAT1. Reintroducing
BCA2-WT and other mutant variants into the shBCA2-KD background would have indicated
which functional domain of BCA2 was essential for the change in NMNAT1 protein, transcript,
and promoter activity level. Preliminary experiments with transfection of BCA2-WT and MT
constructs in the qPCR and promoter assays resulted in significant technical error due to the
variance in transfection efficiency and the sensitivity of the cells to the transfections in the first
place. When these experiments were carried out transiently, insufficient samples (cell-lysates)
were obtained to perform the experiments, and without stable expression of the rescue vectors,
their effect on the functional consequences of shBCA2 and shNMNAT1-KDs could not be
assessed. For this reason, a need to assess the association between BCA2 and NMNAT1 in the
regulation of Warburg-like metabolism was determined.
This was determined because BCA2 and NMNAT1 were found to be reciprocally regulated
in response to glucose concentration in the TNBC cells. Increased glucose concentrations are
known to induce the Warburg effect and enhance tumor-like characteristics of TNBC cells. In
order to determine the role of NMNAT1 in BCA2 dependent regulation of cellular energy,
homeostasis shBCA2/NMNAT1-dKDs were used to inhibit the induction of NMNAT1 associated
with inhibition of BCA2 protein expression.
8.2

Clinical significance
Interestingly, only under conditions of high glucose were the results associated with

shBCA2-KD, shNMNAT1-KD, and shBCA2/NMANT1-KD found to be consistent and yield
statistically reproducible data. If glucose levels were not controlled, or the cells were left in culture
for too long, the phenomena were not observed. This is presumably due to some mechanism by

93
which glucose is regulating BCA2 or NMNAT1 either directly or indirectly, but independently of
each other. In other words, the increase in BCA2 expression associated with shNMNAT1-KD was
not as reproducible under conditions of low glucose as opposed to high glucose. This could be a
consequence of a direct feedback mechanism of glucose on BCA2, or through some indirect
mechanism. Regardless, the results suggest that regulation is dependent on the presence of glucose.
In addition, it is unclear which function of BCA2 is responsible for its regulation of
Warburg-like metabolism. However, the AKT binding domain MT variant presents an interesting
potential explanation of the observed phenomena. AMPK and AKT play critical roles in a double
negative feedback loop in breast cancer, driving the survival of cells as they detach from the
primary site, and helps them survive while detached from the extracellular matrix (ECM) (Saha et
al., 2018). AMPK and AKT appear to function as a molecular switch mediating the survival of
cancer cells during metastatic transformation. The detachment of cells from the matrix triggers
AMPK activity and inhibits AKT activity via upregulation of AKT phosphatase (PHLPP2) (Garcia
& Shaw, 2017). The resultant pAMPKhigh/pAKTlow state was found to be critical for cell survival
in suspension. Matrix reengagement resulted in an AKT-mediated inactivation of AMPK by PP2Cα-thus restoring the pAKThigh/pAMPKlow state, which allows the cells to recommence proliferation
(Saha et al., 2018).
As previously mentioned, BCA2 has been shown to be upregulated in invasive breast cancers
(Burger et al., 2010) and has been shown to be a negative regulator of AMPK activation (Buac et
al., 2013). BCA2 is purported to contain an AKT binding domain, suggesting that BCA2 may be
regulating the activation of AMPK via an AKT dependent signaling cascade (Buac et al., 2013).
In addition, these research findings demonstrated that both BCA2 and NMNAT1 expression is
modulated by the concentration of glucose in the media. The decrease in BCA2 expression and
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decreased availability of glucose to the cell would cause the activation of AMPK through direct
(AMP binding) and indirect (BCA2/AKT dependent) mechanisms (Buac et al., 2013). This
presents a possible mechanism by which BCA2 and AMPK/AKT signaling pathways are regulated
in metastatic transformation. As the tumor mass continues to grow, the available glucose
surrounding the tumor cells decreases, which would decrease the expression of BCA2, and
increase the activation of AMPK and decrease AKT (pAMPKhigh/pAKTlow state) which is essential
for the survival of cancer cells in suspension. Consequently, upon entry into the interstitial fluid
and blood stream, the availability of glucose would once again rise resulting in an increase in
BCA2, which inhibits AMPK switching the cells back to a state of (pAKThigh/pAMPKlow ) which
allows the cells to reattach and recommence proliferation.
A cancer cell’s dynamic ability to respond to a changing environment is essential to its survival,
as well as the ability of the cell to adapt to the high energy and biomass demands of rapid
proliferation (Warburg-like metabolism). The research findings suggest that BCA2 plays a critical
role in the coordination of Warburg-Like metabolism, which is dependent on the expression of
NMNAT1. The inhibition of NMNAT1 expression that is induced by shBCA2-KD is sufficient to
reverse the decrease in Warburg-like metabolism associated with shBCA2-KD.
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Modified metabolism is a hallmark of cancer cell biology known as “The Warburg Effect,”
characterized by increased glucose-consumption and lactate-production, providing the metabolites
and energy necessary for rapid proliferation. Breast-cancer-associated-gene-2 (BCA2) is an E3Ub-ligase known to modulate AMPK, the “master-regulator of energy-homeostasis.” BCA2 is an
oncogene associated with poor patient-survival and breast cancer invasiveness. Phosphoproteomic analysis of siBCA2-MDA-MB-231 knockdown-(KD) revealed enrichment of
Nicotinamide-Nucleotide-Adenylyl-transferase-1 (NMNAT1), an essential enzyme in nuclear
NAD-synthesis and a tumor-suppressor.
Initial experiments demonstrated that glucose concentration was positively correlated with
BCA2 and inversely with NMNAT1 protein expression. shBCA2-KD in MDA-MB-468/-231
reproduced the inverse correlation between BCA2 and NMNAT1. shBCA2 -KD resulted in a
decrease in BCA2 protein (MDA-MB-468: 54% and 49%; MDA-MB-231: 31% and 19%), qPCRtranscript (MDA-MB-468: 45%; MDA-MB-231: 31%) expression.
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shBCA2-KD also resulted in an inverse increase In NMNAT1 qPCR-transcript (MDAMB-468: 146%; MDA-MB-231: 150%) and promoter levels (MDA-MB-468: 409% and 459%;
MDA-MB-231: 175% and 169%). shBCA2-KD was also associated with a decrease in the ratio of
key enzyme associated with Warburg metabolism (LDHA/LDHB); high LDHA/LDHB is
associated with Warburg-like metabolism, and low LDHA/LDHB is associated with decreased
Warburg-like metabolism. Consistent with these findings, shBCA2 -KD resulted in decreased
glucose consumption (MDA-MB-468: 70% and 76%; MDA-MB-231: 75% and 77%), decreased
lactate production (MDA-MB-468: 69% and 72%; MDA-MB-231: 68% and 64%), and decrease
cellular proliferation (MDA-MB-468: 54% and 49%; MDA-MB-231: 31% and 19%). All of these
data are consistent with a role for BCA2 in maintaining Warburg-like metabolism in breast cancer
cell lines, and that inhibition of BCA2 decreases Warburg-like metabolism and tumor cell
proliferation.
In order to investigate the reciprocal role of NMNAT1 in triple negative breast cancer cells
NMNAT1 was knocked down. The shNMNAT1-KD induced BCA2 protein, indicating a potential
reciprocal feedback loop. shNMNAT1 -KD resulted in a decrease in NMNAT1 protein (MDAMB-468: 7070%, 6286 and 8427%; MDA-MB-231: 212%, 202% and 19%), qPCR-transcript
(MDA-MB-468: 45%; MDA-MB-231: 31%) expression.
shBCA2-KD also resulted in an inverse increase in NMNAT1 qPCR-transcript (MDAMB-468: 146%; MDA-MB-231: 150%) and promoter levels (MDA-MB-468: 409% and 459%;
MDA-MB-231: 175% and 169%). shBCA2-KD was also associated with a decrease in the ratio of
key enzyme associated with Warburg metabolism (LDHA/LDHB); high LDHA/LDHB is
associated with Warburg-like metabolism, and low LDHA/LDHB is associated with decreased
Warburg-like metabolism. Consistent with these findings, shBCA2 -KD resulted in decreased
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glucose consumption (MDA-MB-468: 70% and 76%; MDA-MB-231: 75% and 77%), decreased
lactate production (MDA-MB-468: 69% and 72%; MDA-MB-231: 68% and 64%), and decrease
cellular proliferation (MDA-MB-468: 54% and 49%; MDA-MB-231: 31% and 19%). All of these
data are consistent with the role of BCA2 in maintaining Warburg-like metabolism in breast cancer
cell lines, and that inhibition of BCA2 decreases Warburg-like metabolism and tumor cell
proliferation.
In addition, shBCA2/NMNAT1-KD differentially regulates the expression of
LDHA/LDHB. The ratio of LDHA/LDHB modulates lactate/pyruvate equilibria and is a
recognized marker of the relative level of Warburg metabolism. High LDHA/LDHB is positively
correlated with enhanced Warburg activity.
NMNAT1, differentially regulates glucose-consumption and lactate-production. shBCA2KD diminished LDHA/LDHB-ratio, lactate-production, and glucose-consumption. shNMNAT1KD increased the LDHA/LDHB-ratio and lactate-production significantly, with and on glucoseconsumption. shBCA2/NMNAT1-double-KD reversed the effects of shBCA2-KD, resulting in
significant increases in lactate production with an increase of LDHA and LDHB relative to shNT
and shBCA2, and increased LDHA/LDHB ratios relative to shBCA2-KD, as well as rescuing the
effects of shBCA2 on glucose consumption relative to shNT and shBCA2.
Collectively, these data suggest that BCA2 and NMNAT1 modulate breast-cancer-cellmetabolism. The role of energy status indicated by the role of glucose in the regulation of
BCA2/NMNAT1 could provide clues to the significance of these findings and thereby direct future
investigations.
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